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Abstract 
In our daily life, we come across situations where we meet unanticipated 
challenges, we must take certain decisions, pay attention, be flexible and inhibit 
impulsive actions to achieve goal directed behaviour. During these processes, we 
unknowingly use sets of interdependent cognitive processes collectively called ‘executive 
function’. Executive function is mainly regulated by the frontal lobe. Impaired executive 
function is associated with disorders such as schizophrenia, Alzheimer’s disease, autism 
and attention deficit hyperactivity disorder (ADHD).  
In this thesis, we investigated neurotransmitters and interactions among them 
regulating executive function. Further, we investigated mechanisms underlying those 
interactions mediating executive function in rats using an operant conditioning-based set-
shifting task, a common and validated test in animals to assess executive function. In our 
first study, we identified for the first time that systemic injections of dopamine D1 and 
glutamate N-methyl-D-aspartate (NMDA) receptor antagonists cause impaired set-
shifting and increased the occurrence of perseverative errors only after combined 
administration at doses that failed to affect set-shifting following separate injections. The 
discovery of this novel synergistic effect of glutamate and dopamine antagonists on set-
shifting prompted us to undertake our second study to determine if such synergy occurs 
within the medial PFC (mPFC)- an important brain area associated with executive 
function in rodents. Our results confirmed that mPFC is a site where seemingly mild 
suppression of glutamate and dopamine activities, similar to that has been reported in 
schizophrenia brains, may act cooperatively to manifest deficits in executive function via 
increasing perseverative errors. Our third study was to identify molecular mechanisms 
underlying such synergy. We found that protein kinase A (PKA) and extracellular signal-
regulated kinase (ERK1/2) signaling cascades transduce this effect, with ERK1/2 
phosphorylation in mPFC neurons as an obligatory step for set-shifting. 
The present results have substantially advanced our understanding of the 
mechanisms underlying executive function. Our results also point to potential novel 
intracellular targets for therapeutic intervention in cognitive deficits. 
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 Introduction 
1.1 Executive functions 
While driving a car, upon reaching a traffic signal that has just turned amber, the 
first thought that comes to our mind is about the distance of the car from the signal and 
how much time remains before the light turns red. Depending on the assessment, if there 
is sufficient time, we keep driving and get through the traffic signal safely. Alternatively, 
if we think that the signal will turn red before we pass through it, we apply the brakes to 
stop the car at the signal. In the above example, our brain works with enormous speed to 
calculate our distance from the traffic signal, probable time left before light turns red, are 
there any pedestrians looking for crossing the road, other vehicles around our car, etc. 
Information from our current sensory environment and relevant past experiences are 
considered and processed at very fast rate making it possible to drive a car safely. This is 
an example of ‘executive function’ where multiple interdependent cognitive processes 
work together synchronously to carry out a goal directed behaviour. 
Executive function is a higher order cognitive ability comprising working memory, 
behavioural flexibility (set-shifting and reversal learning), attention, problem solving 
ability and inhibition (Gilbert and Burgess 2008; Diamond 2013; Miyake et al. 2000). 
These processes facilitate us to think, plan, get engaged, learn from the outcomes and 
tackle unfamiliar circumstances to carry out goal-directed behaviours in our day-to-day 
life (Elliott, 2003). As described by Funahashi (2001), executive function is ‘a product of 
the co-ordinated operation of various processes to accomplish a particular goal in a 
flexible manner’. It would be difficult to perform daily activities without proper 
executive functioning ability (Damasio, 1994). Various central nervous system (CNS) 
disorders including schizophrenia, Alzheimer’s disease, autism and attention deficit 
hyperactivity disorder (ADHD) show deficits in executive function (Millan et al., 2012). 
Executive function impairments may affect cognition, behaviour and personality. 
Behavioural component involve difficulty in pursuing goals, problem-solving ability and 
switching between possible strategies i.e. behavioural flexibility. These impairments 
affect a patient’s social life drastically and lead to immense economical loss to the 
individual, their family and society.  
3 
 
 
 Executive functioning: Components 
Conventionally, executive function was considered as a single construct, associated 
with higher order cognitive skills (Shallice, 1988). Executive function has also been 
conceptualized as a balanced association of multiple cognitive processes bringing about 
higher order cognitive function (Stuss and Alexander, 2000). As per the latter concept, 
there are three core components of executive functions: inhibition, working memory, and 
behavioural flexibility; all of which are interrelated, interdependent and work together 
(Miyake et al., 2000; Lehto et al., 2003). 
 Inhibition 
In the example of executive functioning given in the first paragraph, when we see 
a traffic light turns amber from green, our brain calculates the probable time left to pass 
through the signal before it turns red. If that time window is too short, our brain 
commands to apply the brakes and stop the car at the signal. This self-inhibition is one of 
the components of executive functioning (Mäntylä et al., 2010). Inhibitory control 
involves regulating one’s thoughts, attention and emotions. It helps us to focus on our 
aim in the presence of distractions. Inhibitory control allows us to avoid impulsive 
responses and to think before making a choice. Inhibition works with other functions like 
attention or working memory, and from our previous learnings help us to avoid making 
incorrect choices. Impaired inhibition can profoundly affect our daily activities causing 
us to react impulsively. CNS disorders including schizophrenia and ADHD, or conditions 
like addiction and mania display pathology of impaired inhibition (Gut-Fayand et al., 
2001; Li and Sinha, 2008; Dumais et al., 2011).  
The frontal lobes are thought to be associated with the regulation of inhibition. It 
was found that patients with frontal damage seized anything in front of them on the 
clinician’s desk, as those objects provided affordances, and inhibition was needed to stop 
motor system to avoid such reactions (Lhermitte, 1983). In a lab experiment, Wallis et al, 
(2001) showed that monkeys with lateral PFC damage cannot control behaviour of 
reaching for food kept behind a transparent barrier provided, that they were trained to 
reach around to get the food previously.  
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 Representative tasks used to assess inhibitory control 
Inhibitory control can be assessed using a number of behavioural tests such as the 
Stroop test (Macleod, 2005), Flanker Task, and Go/No-Go tasks. In the Stroop test, a 
subject sees a series of colour names (black, blue, yellow, green, red). These words 
appear in different colours, sometimes as congruent (e.g., the word blue, written in blue), 
and sometimes non-congruent (e.g., the word blue, written in red). The subject is 
instructed to indicate, as quickly and accurately as possible, the colour in which the word 
is written, regardless if that matches the word itself. 
 Our ability to suppress inappropriate responses in a particular context can be 
assessed by computer-based Flanker Task (Eriksen and Eriksen, 1974). During each trial, 
the subject is presented with a set of arrows on screen as shown below (arranged as A, B, 
C, or D) and a correct response is made by choosing either a left or right button, 
dependent on the direction of the central arrow. The subject’s ability to avoid incorrect 
responses is assessed in this task. 
 
         A 
         B 
         C 
         D 
 
In a separate type of test, Go/no-go task, subjects are required to press a button when a 
stimulus appears; however, on a trial when a particular stimulus is presented, the subject 
must inhibit from pressing the button (Cragg and Nation, 2008).  
 Working memory 
Working memory is an important component of executive function, which is 
characterized by the ability to hold information in the mind temporarily while processing 
it (Baddeley, 2012). An example of working memory would be solving a math problem 
without using paper and pen. Another example of working memory is finishing the 
Figure 1.1 Flanker Task (Eriksen and Eriksen, 1974) 
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meaningful sentence while we are talking, as we need to keep track what has been said 
already and what we should say in order to finish the sentence. Working memory helps us 
to make sense of things which unfold over time as we require to hold in our mind what 
happened earlier and relating that to what comes later (Lett et al., 2014).  
 Representative tasks used to assess working memory 
Working memory tasks are designed such that the subject must keep the 
information provided in mind temporarily and process it to make a correct response. 
Asking a subject to reorder the objects they have read, heard, smelled or seen is an 
excellent measure of working memory. For example, repeating the numbers flashed on 
screen (2, 7, 8, 1, 9) in numerical order (1, 2, 7, 8, 9) or reordering the items just heard 
based on their size (cat, dog, rat, elephant). 
 In Corsi block-tapping task, a tester taps the objects on the screen and following 
that, the subject must tap those objects in the same or opposite sequence in order to get 
the trial correct (Berch et al., 1998; Cragg and Nation, 2007). In the self-ordered pointing 
task (SPOT), a subject sees 12 objects on the screen (drawings or abstract designs), and is 
asked to click one item at a time in any order without repeating the choice until all items 
are clicked. After each choice, feedback is given. In addition to the tasks mentioned, 
researchers have used the N-Back task to assess inhibition (Owen et al., 2005; Kane et 
al., 2007), although it requires high levels of executive function, such as selective and 
sustained attention, thus not making the task selective for working memory (Miller et al., 
2009). 
 Cognitive flexibility 
Cognitive flexibility, which is a core feature of executive function, builds on the 
integration of working memory and inhibition. When we come across a problem which 
could not be solved by the way we know, we take a step back and try to solve it using 
different approaches (changing our point of view). A simple example of behavioural 
flexibility occurs when attempting to open a door; we elect to either pull it inside or push 
it outside. If pulling does not work, we change our approach and try to push the door 
outside. 
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 Representative tasks used to assess cognitive flexibility 
To investigate behavioural flexibility, researchers use set-shifting and task-
switching paradigms (Monsell, 2003). The Wisconsin card sorting task (WCST) is one of 
the oldest tasks to assess behavioural flexibility in patients suffering from CNS disorders 
like schizophrenia (Braff et al., 1991; Gooding et al., 1999; Prentice et al., 2008). In 
WCST, reference cards with stimuli of different coloured shapes are flashed on a screen. 
For each trial, a new test card is offered below the reference cards. The subject must then 
match the test card to one of the reference cards based on the colour, shape, or number of 
the stimuli presented on it. Feedback is provided after each match, enabling the subject to 
acquire the correct rule of sorting the cards. Following a certain number of correct 
responses, the rule is changed without notice, and the subject must shift to a new mode of 
classification to get the trials correct. In set-shifting, ability of subject to switch to new 
strategy is assessed in presence of old strategy which is not valid anymore. 
 As its name implies, task switching involves two tasks and the subject’s ability to 
switch from one task to the other. For example, subject is shown a coloured square with a 
number in the middle. Both sides of screen have a set of response keys: a key asking if 
the number flashed is odd or even, and the other is if the number is lower or higher than 
10. Now based on the colour if it is black, the subject needs to answer higher or lower 
and if the colour is white, answer should be even or odd.  
In both set-shifting or task-switching, errors are due to difficulty in inhibiting 
previously correct strategy, and this tendency is termed as ‘attentional inertia’ (Dick, 
2012; Longman et al., 2014). It was found that the behavioural flexibility is developed in 
children by age of 7-9 (Gupta et al., 2009); during adulthood, it functions at the best and 
declines during old age (Kray and Lindenberger, 2000).  
 Neuroanatomical correlates of executive functioning in human 
Historically executive functioning has been thought to be associated with frontal 
lobes. Patients with frontal cortex damage have shown impaired planning, organizing and 
behavioural disinhibition (Smith and Jonides, 1999; Stuss and Alexander, 2000; Roca et 
al., 2010; Sira and Mateer, 2014). In laboratory settings, such patients have also shown 
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impairments in WCST (Milner, 1963; Nelson, 1976; Stuss et al., 2000). In addition to 
this, patient population suffering from schizophrenia, a disorder with a prefrontal 
pathology, also show executive function impairments (Gooding et al., 1999; Everett et 
al., 2001; Prentice et al., 2008). Further, brain imaging studies in healthy individuals have 
shown that the dorsolateral prefrontal cortex (dlPFC) is one of the areas that is activated 
while performing executive function tests (Funahashi, 2001; Monchi et al., 2001). These 
observations over the years, led to the conclusion that executive function is strongly 
associated with the PFC, and hence, ‘executive function’ and ‘frontal lobe function’ 
became almost interchangeable terms (Ardila, 2008).  
Although the association between the PFC and executive functioning has been 
well-documented, brain imaging studies have also identified the contribution of other 
brain areas in executive functioning (Monchi et al., 2001; Collette and Van Der Linden, 
2002; Salmon and Collette, 2005; Alvarez and Emory, 2006; Collette et al., 2006). 
Neuronal system associated with executive function is complex and interrelated (Gilbert 
and Burgess, 2008). The PFC is highly connected with almost all brain regions including 
parietal, temporal, occipital lobes as well as subcortical and limbic regions, and they 
function interdependently (Adcock, 2000; Manoach et al., 2000; Stuss and Alexander, 
2000; Cole et al., 2012; Zhang et al., 2014). Because of this, areas involved in executive 
functioning may be greatly expanded. Taken together, impaired executive functioning 
may be an outcome of PFC pathology, or it may be related to network disconnections or 
damage to brain regions including mediodorsal thalamus (MDT), striatum, accumbens 
etc. 
 Executive functioning in rodents 
For decades, scientists have routinely used rodents as a main model for brain 
research. Numerous studies have used rats to study executive functions including 
working memory, attention, behavioural flexibility (set-shifting and reversal learning) 
and decision making (Birrell and Brown, 2000; Miller, 2000; Mirza and Bright, 2001; 
Floresco et al., 2009; Auger and Floresco, 2014). Studies have revealed the role of 
different brain nuclei including PFC, striatum, nucleus accumbens (NAc) and ventral 
hippocampus in executive functions (Felix and Levin, 1997; Crofts et al., 2001; Brown 
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and Bowman, 2002; Dalley et al., 2004; Floresco et al., 2006a, 2006b, 2009; 
Boulougouris et al., 2007; Brooks et al., 2012; Lindgren et al., 2013). In our experiments, 
we focused on set-shifting as a measure of behavioural flexibility and studied 
neurotransmitters and the mechanisms associated with set-shifting. 
 Behavioural flexibility in rodents 
The ability to reverse a choice behaviour or the ability to shift a response rule 
when a previously learned strategy does not work has been widely used as a measure of 
behavioural flexibility. Analogous to clinical WCST used by Grant and Berg (1948), set-
shifting tasks have been commonly employed for assessment of cognitive flexibility in 
rodents. These tasks involve training animals to follow a certain rule and once they 
acquire that learning (i.e. form an ‘attentional set’), the rule is changed and ability of 
animals to figure out the new rule in presence of old one is assessed. Rats are required to: 
a) inhibit previously correct strategy which is no longer valid b) keep looking for a new 
strategy which works and c) once figured out, keep using new strategy without going 
back to original one (Floresco et al., 2008). The stimuli used in set-shifting are called 
‘dimensions’ and traditionally they have been visual, related to texture, spatial or 
olfactory in nature. Depending on the stimuli used, there are two versions of set-shifting: 
a) Intra-dimensional and b) Extra-dimensional set-shifting. After forming an initial set, if 
the same type of stimulus used during set-shifting (i.e. after rules are changed), then it is 
called as intra-dimensional set-shifting, and if the different type of stimulus is used for 
latter phase of set-shifting, then it is called as extra-dimensional set-shifting. In 
accordance with clinical studies in patients with prefrontal pathology, rats with PFC 
lesions face more difficulties while performing extra-dimensional set-shifting than intra-
dimensional set-shifting (Dias et al., 1997; Birrell and Brown, 2000). Different types of 
paradigms have been used to assess set-shifting in rodents. The most common examples 
are: a) digging task b) maze task c) operant conditioning-based task. 
 Digging task  
Digging tasks have been used widely and successfully by researches to assess set-
shifting in rodents (Barense et al., 2002; Young et al., 2010; Kos et al., 2011; Heisler et 
al., 2015). Birrell and Brown (2000) used the natural tendency of searching for food in 
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rats. As shown in Figure 1.2, diverse stimulus dimensions are used to distinguish between 
bowls: digging media filling the bowls, olfactory cues added to the medium and the 
texture of the bowls. Rats use tactile or olfactory cues to retrieve food rewards in this 
task. For example, food restricted rats are trained to dig in a bowl with filling medium 
smelling like mint to obtain food rewards during every trial associating mint odour of the 
medium with reward. This is called initial set formation. Next, during the set-shifting, 
rats must switch from olfactory cue to the type of texture of the bowl (sand paper) as a 
strategy to get rewards. So, in latter phase of the task (set-shifting), rats must dig in the 
bowl with sand paper texture regardless of olfactory stimulus.  
 Advantages of this task are that it requires simple set up of instruments, and the 
same rat could be tested more than once using different stimulus dimensions (Wallace et 
al., 2014). Although it also has certain disadvantage like more interference of researcher 
during the task. Furthermore, training rats takes more time as compared to the operant 
task (described below). 
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Figure 1.2 Schematic of the digging task used to assess behavioural flexibility in 
rodents. 
In the digging task, rats are trained to dig in bowls by discriminating them based on odour, 
texture or the medium filled in bowls. In the given example, relevant dimension is odour 
and rats must dig in bowl smelling like mint to get food rewards (initial set formation). 
During extradimensional set-shifting, rats must dig in the bowl with sand paper like texture 
regardless of odour of the bowl.  
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 Maze task  
In the maze task, a plus maze is used where rats shift between two stimulus 
dimensions i.e. visual-cue and spatial-based discrimination strategies (Ragozzino et al., 
2003; Stefani et al., 2003; Floresco et al., 2009). Food restricted rats are initially trained 
(initial set formation) to retrieve food rewards by entering in an arm with distinctive 
visual cue (brightened or darkened arm; Figure 1.3). For the set-shifting, rat must learn to 
turn in specific direction (either left or right) regardless of visual-cue in order to retrieve 
the food rewards. Simple experimental set up is an advantage of using maze task. 
Drawback of maze task would be lack of automaticity as well as an experimenter has to 
handle rats after every trial. 
 
  
Figure 1.3 Schematic of the maze task used to assess behavioural flexibility in rodents. 
For maze-based extradimensional set-shifting task, rats are trained to use a visual-cue 
discrimination strategy i.e., entering the arm with the visual cue by turning to right or left 
(initial set formation). During set-shifting, to earn food rewards, rats must use a response 
discrimination strategy, and make a 90° right turn to enter in an arm to get food reward 
regardless of position of visual-cue stimulus. 
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 Operant-based task  
  Floresco et al. (2008) has adapted the same approach for set-shifting as that of the 
aforementioned plus maze. In an operant box, food restricted rats are trained to press the 
lever associated with an illuminated visual-cue stimulus light to earn food rewards as a 
part of initial training (visual-cue discrimination; Figure 1.4). Once rats achieve the 
criterion for visual-cue discrimination, on the next day, contingencies are altered and now 
rats must respond on one particular lever (response discrimination) during every trial to 
get food rewards regardless of location of illuminated visual-cue stimulus light.  
 Advantage of using this task is that operant conditioning is fully automated, thus 
reducing the interference of an experimenter. Furthermore, parameters like the type of 
errors, omissions and latency to response are precisely recorded in trial by trial manner. 
In addition to this, the associated training procedure in this task is short and robust as 
compared to maze or digging tasks. Moreover, operant conditioning does not have strong 
spatial or olfactory demands (Bizon et al., 2012).  
  
Figure 1.4 Schematic of operant-based task used to assess behavioural flexibility in rodents. 
In operant-based extradimensional set-shifting, rats are trained to respond on the lever with 
illuminated visual-cue stimulus light (i.e. rats use visual-cue discrimination strategy to discriminate 
between the levers). On set-shifting, rats must follow a response discrimination and press one 
particular lever (right or left) regardless of the position of the illuminated visual-cue stimulus light. 
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 Error classification 
Errors committed during set-shifting can be classified in to three categories: 
Perseverative errors: Inability of rats to switch to new strategy give rise to this type of 
errors during set-shifting. Perseverative error is an index of how quickly animals can 
learn use of the correct strategy. 
Regressive errors: While performing set-shifting even though rats try a novel strategy that 
results in a correct trial (food reward), they often go back to the original rule which is 
irrelevant during set-shifting making regressive errors. These regressive errors are an 
index of the rat’s ability to maintain the newly acquired strategy. 
Never-reinforced errors: While performing set-shifting, animals try to explore new 
response choices to figure out the novel strategies which could result in a correct 
response. During this process, rats try certain approaches that they never learnt during the 
initial acquisition, only to discover that it also does not yield a food reward during the 
set-shifting task. This type of error is called a never-reinforced error. Never-reinforced 
errors are an index of how readily rats can ignore certain strategies which do not result in 
a correct response. 
 
 Neural circuits subserving behavioural flexibility in rodents  
Behavioural flexibility is not a unitary phenomenon, rather, it has been 
conceptualized as different functions working together. To finish set-shifting 
successfully, animals must meet three requirements of the task: a) Inhibit a previously 
correct strategy which is now irrelevant during set-shifting. b) Keep looking for a new 
strategy which could give food rewards. c) Once a new strategy is found, keep using it, 
and avoid going back to the previously correct rule. Because different brain nuclei are 
associated with different components mentioned, a successful set-shifting performance is 
thought to be the result of brain circuitry involving number of brain regions rather than 
one specific nucleus (Block et al., 2007; Floresco et al., 2009). 
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 Prefrontal Cortex (PFC) 
From the studies in human, non-human primates as well as rodents, it is well 
known that PFC is strongly implicated in behavioural flexibility (Brown and Tait, 2016). 
Inactivation or damaging medial prefrontal cortex (mPFC) in rat results in impaired set-
shifting performance without affecting initial learning (initial set formation) (Ragozzino 
et al., 1999a; b; Floresco et al., 2008). Following inactivation/lesioning of mPFC, 
perseverative errors were found to be increased (rats are not able to switch to new rule, 
hence repeating the same incorrect response despite not receiving any food rewards). On 
the other hand, inactivation of orbitofrontal cortex (OFC) caused impaired reversal 
learning in rats (Ghods-Sharifi et al., 2008). Interestingly, inactivation of mPFC did not 
affect reversal learning, and lesioning OFC did not have any effect on set-shifting; 
findings which suggest that although set-shifting and reversal learning are components of 
behavioural flexibility, they are regulated by different regions of the PFC. Furthermore, 
increased perseverance is the abnormality shared by rats with mPFC damage and the 
patients with schizophrenia with frontal lobe pathology in set-shifting and WCST 
respectively, suggesting PFC has similar role in executive functioning across species (For 
review, Brown and Tait, 2016). 
 Mediodorsal Thalamus (MDT) 
Mediodorsal thalamus has reciprocal connectivity with the PFC (Groenewegen, 
1988). This anatomical association with PFC suggest that MDT may contribute to 
behavioural flexibility. The role of MDT in a simpler form of behavioural flexibility i.e., 
reversal learning is controversial as some studies report impairments in reversal learning 
following MDT lesioning (Means et al., 1975; Chudasama et al., 2001; Parnaudeau et al., 
2015) while others did not see any impairments (Tigner, 1974; Beracochea et al., 1989). 
On the other hand, lesioning MDT produced increased perseverance in rodents in a set-
shifting task which is a more complex behaviour than reversal learning (Hunt and 
Aggleton, 1998). Furthermore, inactivating MDT did not affect the initial learning phase 
in set-shifting, suggesting the MDT is associated with shifting strategy and not general 
learning (Block et al., 2007). 
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 Clinical brain imaging studies have shown activation of MDT following incorrect 
response in WCST suggesting it may be acting as a trigger to switch the strategy (Monchi 
et al., 2001). Thus, across species, MDT is associated with behavioural flexibility, and 
abnormal functioning of MDT results in increased perseverance. 
 Nucleus Accumbens (NAc) 
  Floresco et al. (2006a), investigated effect of inactivation of NAc-Core and NAc-
Shell on maze-based set-shifting task performance. It was found that inactivation of NAc-
Core did not affect initial acquisition but impaired set-shifting. Type of errors committed 
during set-shifting were ‘regressive’ and ‘never-reinforced’; error profiles different than 
perseverative error profile associated with mPFC or MDT lesioning. Increased regressive 
errors meant that rats were not able to hold on to the new strategy and more often they 
went back to the previously correct strategy suggesting that NAc-Core plays important 
role in maintenance of a novel response. Never-reinforced errors are considered as an 
index of how quickly rats can get rid of the strategy which would not give food pellet 
(correct response) (Floresco et al., 2008). An increase in never-reinforced errors suggests 
that NAc-Core mediates the inhibition of unsuitable response choices through learning of 
a novel strategy. Inactivation of NAc-Shell neither affected initial acquisition nor the set-
shifting. 
 Striatum 
Inactivation of striatum did not affect initial acquisition in rats but impaired set-
shifting. Errors committed were regressive in nature suggesting that striatum plays an 
important role in maintaining newly learnt strategy (Ragozzino et al., 2002b; Haluk and 
Floresco, 2009). 
 Neurotransmitters associated with behavioural flexibility 
Various pharmacological studies in animals have provided evidence for 
involvement of different neurotransmitter systems regulating set-shifting. Most 
commonly, gamma-Aminobutyric acid (GABA), dopamine, glutamate and have been 
studied for their role in in behavioural flexibility. 
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 GABA 
Involvement of GABAergic neurotransmitter in cognition has been the topic of 
discussion for last two decades. GABA has got the attention of researchers due to its 
involvement in the prefrontal pathophysiology of schizophrenia and possible role in 
cognitive impairments associated with schizophrenia (Coyle, 2004; Lewis et al., 2008; 
Vinkers et al., 2010; Lett et al., 2014). Since then several studies in human as well as in 
animals have investigated the role of GABA in executive functions including working 
memory, attention and behavioural flexibility (Michels et al., 2012; Auger and Floresco, 
2014; Banuelos et al., 2014; Chen et al., 2014). 
 Enomoto et al. (2011) studied effect of intra-mPFC infusion of bicuculline 
(GABA-A receptor antagonist) on set-shifting. It was found that, bicuculline significantly 
impaired set-shifting in rats. Impaired set-shifting resulted from increased perseverative 
errors without any effect on regressive and never-reinforced errors; an error profile 
similar to mPFC inactivation studies (Ragozzino et al., 1999a; Floresco et al., 2008). 
 Dopamine 
Historically, the role of prefrontal dopamine has been examined for its 
contribution in executive functioning. Evidence from human as well as animal studies 
have confirmed that normal dopamine receptor functioning (D1/D2) is essential for 
normal executive functions including working memory, attention and behavioural 
flexibility (Sawaguchi and Goldman-Rakic, 1994; Müller et al., 1998; Misener et al., 
2004; Vijayraghavan et al., 2007; Floresco, 2013). Furthermore, decreased number of 
dopamine D1 receptors in dlPFC of schizophrenic patients was correlated with the poor 
performance on a working memory task (Okubo et al., 1997; Akil et al., 1999).  
 Considering the role of dopaminergic neurotransmitter in cognitive processes, 
researchers studied the involvement of dopamine in behavioural flexibility using 
pharmacological approaches in rodents. For example, intra-mPFC infusion of dopamine 
D1 receptor antagonist impaired set-shifting without affecting initial acquisition 
(Ragozzino, 2002a; Gauthier et al., 2014). Interestingly, stimulation of D1 receptors did 
not improve set-shifting (Floresco et al., 2006b), a finding in line with Fletcher et al. 
(2005), where acute intra-mPFC infusion of D1 receptor agonist treatment per se did not 
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affect set-shifting but reversed set-shifting impairments in amphetamine sensitized rats. 
Further, intra-mPFC infusions of dopamine D2 receptor antagonist impaired set-shifting 
set-shifting by increasing perseverance whereas stimulation of D2 receptors in the mPFC 
did not affect set-shifting. In addition to this,  while D4 receptor agonist impaired set-
shifting performance, stimulation of D4 receptors by an agonist improved the set-shifting 
above control level (Floresco et al., 2006b). These findings indicate that the “inverted-U” 
shaped function underlying dopamine receptor regulating working memory does not 
appear to hold true for set-shifting function mediated by the PFC. This finding is in 
accordance with  
 Glutamate 
In the brain, glutamate is a major excitatory neurotransmitter. Glutamate N-
methyl-D-aspartate (NMDA) receptors regulate synaptic plasticity i.e. long-term 
potentiation (LTP) and cognition (Villarreal et al., 2002). NMDA receptor antagonists 
including ketamine and phencyclidine (PCP) cause cognitive symptoms of schizophrenia 
in healthy volunteers or exacerbate these impairments in schizophrenic patients (Malhotra 
et al., 1996, 1997; Coyle and Tsai, 2004; Morgan et al., 2004; Morris et al., 2005). This 
led to glutamatergic hypothesis of schizophrenia where NMDA altered functioning was 
related to impaired cognition in schizophrenic patients (Coyle, 1996, 2006; Tsai and 
Coyle, 2002; Paz et al., 2008). 
 Due to deep association of glutamate with cognition, researchers investigated if 
glutamate is involved in controlling executive functions in humans as well as animals. In 
a clinical study (Krystal et al., 2000) found that administration of sub-anesthetic dose of 
ketamine in healthy volunteers impaired their performance in WCST. In animal studies, 
normal functioning of NMDA receptors was found to be essential for working memory as 
well as attention (Murphy et al., 2005; Baviera et al., 2008; Smith et al., 2011; Wang et 
al., 2012b; Su et al., 2014; Auger and Floresco, 2017).  
In animals, behavioural flexibility was found to be regulated by NMDA receptors. 
Intra-mPFC infusion of NMDA receptor antagonist (MK-801) impaired set-shifting and 
increasing perseverative errors in animals (Stefani and Moghaddam, 2005). This finding 
18 
 
 
was replicated by acute or repeated systemic injections of either MK-801, PCP or 
ketamine in animals (Rodefer et al., 2005; Egerton et al., 2008; McLean et al., 2008). 
 Dopamine-glutamate interactions 
Both dopamine and glutamate abnormalities in the PFC are thought to be 
associated with cognitive pathology of schizophrenia (Akil et al., 1999; Coyle, 2006). 
Role of individual neurotransmitters regulating executive functions has been studied. 
Although the interaction between dopamine and glutamate regulating different 
behaviours has been investigated, its role in executive function is yet to be explored 
sufficiently. 
A number of studies have investigated interaction between D1 and NMDA 
receptors regulating different behaviours. It was found that combined infusion of sub-
effective doses of D1 and NMDA receptor antagonists in the mPFC or NAc-Core 
impaired instrumental learning in rats (Smith-Roe and Kelley, 2000; Baldwin et al., 
2002b). Similarly, co-infusion of NMDA and D1 receptor antagonists on contralateral 
sides of amygdala impaired glucose-conditioned learning of flavor preference in rats; co-
infusion of one of the antagonists on one side and vehicle on the other side did not show 
any effect on behaviour suggesting that, blockade of both D1 and NMDA receptors was 
essential to cause impairment (Touzani et al., 2013). Furthermore, functional striatal 
NMDA channels are needed to control D1-stimulated locomotor behaviour (Kreipke and 
Walker, 2004). In addition to this, deletion of NR1 subunit of NMDA receptors in the 
NAc was found to attenuate apomorphine-induced decrease in acoustic startle response in 
rats suggesting an interaction between D1-NMDA receptors (Glass et al., 2013). Along 
with behaviours mentioned above, D1-NMDA interactions were found to control higher 
cognitive functions. Intra-medial dorsal striatum co-infusion of D1 and NMDA receptor 
antagonists at respective ineffective dose significantly decreased accuracy of visual 
discrimination in the 5 choice serial reaction time task (5CSRT) in rats (Agnoli and Carli, 
2011). Moreover, Nai et al. (2010) reported that uncoupling of D1-NMDA receptor 
interaction by using an interfering peptide (TAT-D1-t2 peptide) eliminates D1 receptor-
induced upregulation of NMDA mediated LTP in rat hippocampal cultures. In addition to 
this, in the same study, intra-hippocampal infusion of TAT-D1-t2 peptide impaired 
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working memory in mice. Intra-mPFC infusion of D1 receptor agonist rescued set-
shifting in amphetamine-sensitized rats (Fletcher et al., 2005) suggesting D1-NMDA 
interaction controlling behaviour. 
From the aforementioned literature, it seems that there are strong interactions 
between D1 and NMDA receptors regulating different types of behaviours in animals. 
These behavioural findings were supported by number of electrophysiology studies 
showing synergistic interaction between dopamine D1 and glutamate NMDA receptors. 
Kruse et al. (2009) reported that, D1 receptors and NMDA receptors are co-localized in 
single pyramidal neuron as well as GABA interneurons in the adult rat PFC. In the same 
study, activation of D1 receptors was found to potentiate NMDA receptor mediated 
increase in cytosolic calcium ions. Activation of D1 receptors upregulated NMDA 
receptor-mediated LTP in the hippocampus, PFC or striatum (Calabresi et al., 2000; 
Gurden et al., 2000; Kerr and Wickens, 2001; Nai et al., 2010). Furthermore, both D1 and 
NMDA receptors potentiated each other’s expression at synaptic membrane in PFC and 
striatum (Jay, 2003; Hallett et al., 2006; Scott et al., 2006; Castner and Williams, 2007; 
Gao and Wolf, 2008).  
 Although interactions between D1-NMDA receptors are studied in detail, direct 
evidence of role of this interaction regulating set-shifting is still to be understood.  
 Mechanisms underlying D1-NMDA interactions 
From the above-mentioned studies, it seems that interactions between D1-NMDA 
receptors are important. A number of studies investigated the mechanisms underpinning 
D1-NMDA receptor interactions which are complex in nature. These interactions either 
facilitate or inhibit responses to receptor activation (Cepeda and Levine, 2006). 
 D1-NMDA receptor interactions through protein kinase A 
(PKA) signaling cascade  
D1-NMDA receptor interactions have been reported to be mediated by number of 
molecular signaling cascades in the PFC as well as the striatum (Kerr and Wickens, 2001; 
Cepeda and Levine, 2006; Kruse et al., 2009). The most important is of D1 activated 
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cAMP-PKA cascade which leads to a multitude of outcomes including phosphorylation 
of NR1 subunits of NMDA receptors (Snyder et al., 1998) and activation of voltage-gated 
Ca++ channels (Cepeda et al., 1998; Tseng and O’Donnell, 2004; Kruse et al., 2009). On 
the other hand, antagonizing D1 receptors attenuated the PKA-mediated phosphorylation 
of NR1 subunits (Edwards et al., 2002), and inhibiting PKA prevented D1-induced 
NMDA-mediated calcium signaling (Kruse et al., 2009). Thus, PKA is an important 
signaling molecule used by D1-NMDA receptor interactions. Table 1.1 summarizes D1-
NMDA interactions mediated through PKA cascade. 
 D1-NMDA receptor interactions through extracellular signal-
regulated kinase (ERK) signaling cascade 
Sarantis et al. (2009) showed that combined treatment with sub-effective doses of 
D1 agonist and NMDA in the mPFC or hippocampus slices caused an increase in 
phosphorylation of NR1 and NR2B subunits of NMDA receptors. Interestingly, the 
signaling pathway associated with the synergism involved phosphorylation of ERK1/2. 
However, unlike what was described in the striatum, D1  ERK1/2 cascade is 
independent of DARPP-32 as an intermediary in the PFC. In the same study, authors 
stated the possibility of an involvement of PKA and protein kinase C (PKC) which would 
activate ERK1/2 signaling pathway as reported previously by Cahill et al. (2014). In 
agreement with the study of Sarantis et al. (2009), involvement of ERK1/2 signaling in 
D1-NMDA interaction was also reported by others in the hippocampus and NAc 
(Papadeas et al., 2004; Haberny and Carr, 2005; Sarantis et al., 2012). 
  Physical D1-NMDA receptor interactions 
Direct physical interaction between D1 and NMDA receptors has also been 
reported in hippocampal neuronal cultures, PFC and the striatum (Lee et al., 2002; Pei et 
al., 2004; Hu et al., 2010; Groveman et al., 2012). Protein-protein interactions between C-
terminals of D1 receptors and NMDA receptor subunits NR1 or NR2A allow direct 
cross-talk between two receptors (Lee et al., 2002; Fiorentini et al., 2003; Pei et al., 
2004). Interaction of D1 with NR1 increases plasma membrane insertion of D1 receptors 
upregulating D1 receptor function and this upregulation was found to be mediated 
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through Fyn kinase, a family member of Src kinase, in PFC (Pei et al., 2004; Hu et al., 
2010). Table 1.1 summarizes D1-NMDA interactions mediated through direct protein-
protein interaction. 
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Table 1.1 Summary of D1 and NMDA receptor interactions 
Receptor 
activated 
Preparation Region Effect Mechanism References 
Physical 
interactions 
          
NMDA Organotypic 
cultures 
Striatum D1 receptors 
in spines 
Allosteric 
change, 
diffusion trap 
Scott et al., (2006) 
NMDA COS7, cell 
cultures 
Hippocampus D1 receptors 
in membrane 
D1-NR1 
binding 
Pei et al., (2004) 
D1 HEK293, cell 
cultures 
Hippocampus NMDA 
currents 
Excitotoxicity 
D1-NR2A 
binding D1-
NR1 binding 
Lee et al., (2002) 
D1 HEK293, 
COS7, PSD 
Striatum Translocation 
of D1-NR1 
D1 agonist–
induced 
internalization 
Oligomerization 
of D1 and NR1 
Fiorentini et al., 
(2003) 
Second messenger–mediated interactions       
NMDA Cell cultures Striatum D1 receptors 
in spines 
Ca++-dependent Scott et al., (2002) 
D1 Synaptosomes 
from brain 
slices 
Striatum NR1, NR2A, 
NR2B in 
synaptosomes 
Fyn protein 
tyrosine kinase 
(Dunah and 
Standaert, 2001; 
Fiorentini et al., 
2003) 
D1 and 
NMDA 
Brain slices, 
oocytes, 
dissociated 
cells 
Striatum, 
cortex 
NMDA 
responses 
cAMP–PKA–
DARPP-32, 
Ca++ 
(Cepeda et al., 
1992, 1998; 
Snyder et al., 
1998; Wang and 
O’Donnell, 2001; 
Flores-Hernández 
et al., 2002; 
Seamans and 
Yang, 2004; 
Tseng and 
O’Donnell, 2004) 
D1 and 
NMDA 
Brain slices, 
cells 
N. 
accumbens, 
cortex 
NMDA 
responses 
PKC, Ca++ (Chergui and 
Lacey, 1999; 
Chen et al., 2004) 
Review Cepeda and Levine (2006) 
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1.2 Thesis objectives and hypotheses  
Based on the overview of the literature, deficits in the behavioural flexibility and 
increased propensity of perseverative errors are core cognitive abnormalities in certain 
CNS disorders, including, schizophrenia, and are associated with abnormal functioning of 
interconnected brain areas, including the PFC. Post-mortem findings and previous animal 
studies showed marked decreases of glutamate and dopamine levels in the PFC 
individually and is sufficient to cause increased perseverative errors leading to 
impairment in behavioural flexibility. However, recent in vivo imaging studies have 
shown that, in living patients the loss of these neurotransmitters is minimal. 
Consequently, our overall hypothesis was that the minimal loss of glutamate or 
dopamine function is sufficient to produce impaired behavioural flexibility by 
increased perseverative errors provided those losses co-occur in the brain. This also 
suggests that there may by synergy between glutamate and dopamine neurotransmitter 
abnormalities. In order to test our overall hypothesis, an operant conditioning-based set-
shifting paradigm was used. Following three studies were undertaken to test our overall 
hypothesis and to elucidate associated molecular signaling mechanisms mediating 
proposed synergy between deficiencies in neurotransmitter actions and how they are 
relevant to behavioral flexibility. 
 Study I 
The role of dopamine D1 and glutamate NMDA receptors is well-recognized in 
the regulation of memory, cognition and executive functioning (Okubo et al., 1997; 
Nieoullon, 2002; Volk et al., 2015; Thomas et al., 2017; Akil et al., 2013). Contrary to 
the notion based on post-mortem studies, recent in vivo imaging studies have shown that 
the changes in the dopamine and glutamate levels in the PFC of living schizophrenic 
patients are very subtle (Laruelle et al., 2003; Théberge et al., 2007; Ohrmann et al., 
2007; Galińska et al., 2009; Rowland et al., 2009; Aoyama et al., 2011; Seese et al., 2011; 
Szulc et al., 2011; Goto et al., 2012; Kegeles et al., 2012; Slifstein et al., 2015; Howes et 
al., 2015). It is possible that these subtle alterations in neurotransmitter systems 
ultimately result in noticeable cognitive impairments. In animal studies, the individual 
role of dopamine and glutamate has been investigated in regulating set-shifting behaviour 
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and results showed that large decreases in individual transmitters in different brain areas 
could impair set-shifting performance (Stefani et al., 2003; Haluk and Floresco, 2009; 
Tait et al., 2014; Gauthier et al., 2014). Functional neuroimaging studies have indicated 
that a number of cortical and subcortical areas including dlPFC, anterior cingulate cortex, 
striatum, hippocampus and the MDT are associated with successful performance of the 
WCST (Stratta et al., 1997; Rüsch et al., 2007; Wilmsmeier et al., 2010; Pedersen et al., 
2012; Young et al., 2000; Kemether et al., 2003). In agreement with this, several animal 
studies have shown that, inactivation of number of brain areas or connections among 
them could lead to impaired set-shifting. Since, the hypothesized interaction between 
dopamine-glutamate neurotransmitters could occur in several potential areas as shown in 
animal studies (Block et al., 2007; Floresco et al., 2008; 2009), we decided to use 
systemic route of drug administration to target brain circuitry rather than specific nuclei. 
We tested effect of combined systemic administration of dopamine D1 and glutamate 
NMDA receptor antagonists on set-shifting behaviour in normal rats.  
The following is the specific aim of the study I: 
To determine the effect of systemic combined administration of “behaviourally sub-
effective” doses of D1 and NMDA receptor antagonists on set-shifting in normal 
rats. 
 Study II 
Across species, PFC is associated with executive functioning (Abbruzzese et al., 
1996; Ragozzino et al., 199b; Floresco et al., 2008; Moore et al., 2009). Patients with 
prefrontal pathology of schizophrenia or accidental frontal lobe damage show impaired 
executive functions (Milner, 1963; Nelson, 1976; Smith and Jonides, 1999; Stuss and 
Alexander, 2000; Stuss et al., 2000; Roca et al., 2010; Sira and Mateer, 2014). In clinical 
studies, prefrontal cortical dopamine as well as glutamate neurotransmitters were 
proposed to regulate cognition and abnormal functioning of these neurotransmitters may 
impair cognition in schizophrenia (Krystal et al., 2000; Coyle, 2006; Akil et al., 2013). In 
line with the clinical studies, findings from animal studies confirm essential role of 
dopamine and glutamate neurotransmitters individually in the mPFC for normal 
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executive functioning (Ragozzino, 2002a; Stefani and Moghaddam et al., 2003; Gauthier 
et al 2014). In addition, several behaviours other than executive function, are regulated by 
interaction between D1 and NMDA receptors (Smith-Roe and Kelley, 2000; Baldwin et 
al., 2002; Fletcher et al., 2005; Nai et al., 2010; Agnoli and Carli, 2011; Touzani et al., 
2013; Glass et al., 2013). 
 From our first study, it was evident that the systemic combined administration of 
behaviourally sub-effective doses of D1 and NMDA receptor antagonists caused set-
shifting impairments and produced error profile similar to inactivation or lesioning 
studies in mPFC (Everett et al., 2001; Block et al., 2007; Floresco et al., 2008; Roca et 
al., 2010). Therefore, we hypothesized that, PFC is one of the brain sites where 
synergism between dopamine and glutamate abnormalities could occur. In the second 
study, we sought to find out if the mPFC is associated with synergism between D1-
NMDA receptor antagonists. To test our hypothesis, we infused mPFC of normal rats 
with D1 or NMDA receptor antagonists individually to determine their dose-response 
profile in set-shifting. The highest but ineffective doses of these antagonists were then 
combined to determine whether there is a synergism between them causing increased 
perseverance in set-shifting. 
The following is the specific aim of study II: 
To determine the effect of intra-mPFC co-infusion of ‘behaviourally sub-effective’ 
doses of D1 and NMDA receptor antagonists on set-shifting in normal rats. 
 Study III 
From the literature, it was evident that in different areas of the brain, interactions 
between D1-NMDA receptors may use mainly three molecular signaling pathways: PKA, 
ERK or direct protein-protein interactions between D1 and NMDA receptor complexes 
through Fyn kinase. Interestingly, all main three pathways (PKA, ERK and Fyn kinase 
mediated protein-protein interaction) have been implicated in the pathology of 
schizophrenia (Tardito et al., 2001; Rybakowski et al., 2007; Yuan et al., 2010; Hahn, 
2011; Kunii et al., 2011; Wang et al., 2015).  
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In the mPFC, D1-NMDA receptors may interact via PKA signaling cascade to 
regulate learning in rats (Baldwin et al., 2002). Furthermore, PKA was also found to 
regulate synergistic effect of D1-NMDA receptors on excitability of pyramidal neuron in 
the mPFC (Wang and O’Donnell, 2001). Along with PKA, ERK signaling was also found 
to regulate D1-NMDA receptor interaction in the mPFC (Sarantis et al., 2009; Nagai et 
al., 2007). Moreover, physical interaction between D1-NMDA receptors seems to 
potentiate each other’s function (Gao and Wolf, 2008; Hu et al., 2010).  
From results obtained in the study II, it appears that mPFC is one of the nuclei 
where D1-NMDA receptors are interacting with each other to regulate set-shifting 
behaviour. Thus, we hypothesized that molecular mechanisms underlying D1-NMDA 
receptor interaction will use one or more of the following pathways in mPFC neurons to 
regulate set-shifting behaviour: a) PKA b) ERK1/2 c) Fyn kinase-mediated interaction 
between D1-NMDA receptors. To test our hypothesis, we performed a series of the 
following experiments: a) effects of elevating PKA levels in the mPFC in animals 
receiving intra mPFC infusion of a combination of D1 and NMDA antagonists that 
disrupted set-shifting performance in study II; b) effects of inhibiting ERK1/2 
phosphorylation on set-shifting performance in naïve rats; and c) effect of inhibiting Fyn 
kinase in the mPFC on set-shifting behaviour. 
Following specific aims were tested in this study: 
1. To determine the effect of elevating PKA in the mPFC on D1-NMDA receptor 
antagonist combination (from study II)-induced impaired set-shifting. 
2. To determine the effect of inhibiting Fyn kinase and hence to verify if direct D1 
 NMDA receptor cross-talk facilitates set-shifting in normal rats. 
3. To determine the effect of inhibiting ERK1/2-phosphorylation in the mPFC using 
MAPK (mitogen-activated protein kinase) inhibitors on set-shifting in normal 
rats. 
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 Combination of behaviourally sub-effective doses of 
glutamate NMDA and dopamine D1 receptor antagonists 
impairs executive function1 
2.1 Abstract 
Impairment of executive function is a core feature of schizophrenia. Preclinical 
studies indicate that injections of either N-methyl D-aspartate (NMDA) or dopamine D1 
receptor blockers impair executive function. Despite the prevailing notion based on post-
mortem findings in schizophrenia that cortical areas have marked suppression of 
glutamate and dopamine, recent in vivo imaging studies suggest that abnormalities of 
these neurotransmitters in living patients may be quite subtle. Thus, we hypothesized that 
modest impairments in both glutamate and dopamine function can act synergistically to 
cause executive dysfunction. In the present study, we investigated the effect of combined 
administration of “behaviourally sub-effective” doses of NMDA and dopamine D1 
receptor antagonists on executive function. An operant conditioning-based set-shifting 
task was used to assess behavioural flexibility in rats that were systemically injected with 
NMDA and dopamine D1 receptor antagonists individually or in combination prior to 
task performance. Separate injections of the NMDA receptor antagonist, MK-801, and 
the dopamine D1 receptor antagonist, SCH 23390, at low doses did not impair set-
shifting; however, the combined administration of these same behaviourally sub-effective 
doses of the antagonists significantly impaired the performance during set-shifting 
without affecting learning, retrieval of the memory of the initial rule, latency of responses 
or the number of omissions. The combined treatment also produced an increased number 
of perseverative errors. Our results indicate that NMDA and D1 receptor blockade act 
synergistically to cause behavioural inflexibility, and as such, subtle abnormalities in 
glutamatergic and dopaminergic systems may act cooperatively to cause deficits in 
executive function. 
 
1 Chapter 2 has been published as: Desai SJ, Allman BL, Rajakumar N (2017) 
Combination of behaviourally sub-effective doses of glutamate NMDA and dopamine D1 
receptor antagonists impairs executive function. Behav Brain Res 323:24-31. 
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2.2 Introduction 
Executive function is a complex phenomenon comprising attention, working 
memory, planning, reasoning, sequencing, inhibitory control and cognitive flexibility 
(Robbins et al., 1996). Severe impairment of executive function is a core feature of 
schizophrenia, and is an important determinant of long-term outcome and quality of life 
of these patients (Hutton et al., 1998; Krieger et al., 2005; Holthausen et al., 2007; 
Penadés et al., 2010). In addition to challenges with daily activities, patients with 
impaired executive function demonstrate difficulty performing standardized 
neuropsychological assessments of behavioural flexibility, such as the Wisconsin card 
sorting test (WCST) (Anderson et al., 1991; Prentice et al., 2008). Based on the findings 
from functional neuroimaging studies, a variety of cortical and subcortical areas have 
been implicated in the successful performance of the WCST, most notably the 
dorsolateral prefrontal cortex (dlPFC) anterior cingulate cortex, striatum, hippocampus 
and the mediodorsal nucleus of the thalamus (MDT) (Stratta et al., 1997; Rüsch et al., 
2007; Wilmsmeier et al., 2010; Pedersen et al., 2012). Similarly, preclinical studies in 
rodents have confirmed that the aforementioned brain regions are necessary for 
behavioural flexibility during such tasks as set-shifting (Ragozzino et al., 1999; 
Ragozzino et al., 2002; Block et al., 2007; Floresco et al., 2008, 2009; Haluk and 
Floresco, 2009).  
Post-mortem studies on schizophrenic brains have demonstrated a significant loss 
of glutamic acid decarboxylase-67 (GAD67) expression across multiple cortical areas 
indicating decreased activity of -amino butyric acid (GABA) (Woo et al., 1998; 
Hashimoto et al., 2003; Ishikawa et al., 2004; Duncan et al., 2010). Furthermore, a 
marked loss of dopaminergic fibers was described in the dlPFC of post-mortem brains of 
schizophrenia (Knable and Weinberger, 1997; Akil et al., 1999), and there was a severe 
loss of dendritic spines within the prefrontal cortex and the hippocampus, indicating 
possible loss of glutamatergic synapses in schizophrenia (Glantz and Lewis, 2000). 
Decreased levels of a number of proteins associated with glutamatergic synapses in the 
thalamus were also identified (Clinton and Meador-Woodruff, 2004). In addition, a 
significant loss of neurons has been described in the mediodorsal nucleus of the thalamus 
in schizophrenia brains (Galińska et al., 2009). Overall, available post-mortem studies of 
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schizophrenia, despite the heterogeneity of the disorder, point to a severe loss of 
glutamatergic, dopaminergic and GABAergic function in multiple brain areas in 
schizophrenia. Consistent with the findings, preclinical studies using set-shifting tasks 
have revealed that the separate administration of relatively high doses of either D1 
dopamine, N-methyl D-aspartate (NMDA) or GABA-A receptor antagonists worsens 
performance (Stefani and Moghaddam, 2005; Enomoto et al., 2011; Floresco, 2013; 
Nikiforuk et al., 2016), suggesting that decreased activity of any one of these 
neurotransmitters could underlie the impaired behavioural flexibility in schizophrenia.  
Although the collective results of post-mortem studies on schizophrenia brains 
and preclinical models suggest that severe deficits in GABA, dopamine or glutamate 
function may be responsible for the impairments in executive function observed in 
schizophrenia, the results of in vivo imaging studies on schizophrenic patients 
consistently provide a contradictory view. Studies using in vivo magnetic resonance 
spectroscopy (MRS) or positron emission tomography (PET) have identified that levels 
of glutamate, dopamine and GABA in the dlPFC and thalamus are not different or 
slightly altered in schizophrenia patients in comparison to control groups (Théberge et al., 
2007; Ohrmann et al., 2007; Galińska et al., 2009; Rowland et al., 2009; Aoyama et al., 
2011; Seese et al., 2011; Szulc et al., 2011; Goto et al., 2012; Kegeles et al., 2012; 
Frankle et al., 2015; Slifstein et al., 2015). Based on the above MRS and PET findings, it 
is conceivable that the extent of suppression of neurotransmitter function predicted based 
on post-mortem findings may not apply in patients living with schizophrenia, and if at all, 
the differences may be subtle, perhaps due to compensatory mechanisms. Furthermore, 
recent theories postulate that certain GABA abnormalities in schizophrenia might be 
compensatory (Gonzalez-Burgos et al., 2011; Lewis, 2014). Consequently, we 
hypothesized that subtle abnormalities in the glutamate and dopamine neurotransmitter 
systems in functionally-connected cortical and subcortical areas may cooperate 
synergistically to impair executive function in schizophrenia; an experimental 
consideration which had not been addressed in previous preclinical rodent models as they 
only targeted a single neurotransmitter system at a given time.  
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Among dopamine receptors, D1 receptor subtype is more commonly implicated in 
executive function (Duncan et al., 2010; Szulc et al., 2011). In addition, in vivo imaging 
studies have identified increased D1 receptor levels in the dlPFC in schizophrenia 
patients (Ozonoff et al., 2004). Consequently, in the present study, we focused on D1 
receptor antagonism. Ultimately, we investigated the potential synergistic effect of the 
combined administration of “behaviourally sub-effective” doses of D1 and NMDA 
receptor antagonists on set-shifting in rats performing a lever-pressing task that required 
them to shift between visual-cue and egocentric spatial response-based discrimination 
strategies according to the paradigm of Enomoto et al. (2011). To that end, in separate 
groups of rats, we first determined the doses of the D1 antagonist, SCH 23390, and 
NMDA uncompetitive antagonist, MK-801, which when systemically administered 
alone, failed to worsen set-shifting performance compared to vehicle-treated controls. 
Next, these behaviourally sub-effective doses were co-administered systemically to a 
separate group of rats, and the results compared to controls as well as rats that received a 
higher (i.e., “effective”) dose of MK-801 delivered alone. 
2.3 Materials and methods 
 Animals 
Adult male Sprague Dawley rats (Charles River, Quebec, Canada) weighing 325-
350 g at the beginning of the study were housed individually in an animal facility with 
temperature and humidity controlled rooms (24±2 °C, relative humidity 55±10%), 12 h 
light/dark cycle (lights on at 7:00 am). Animals were food restricted to ~85% of their free 
feeding body weight. During food restriction, rats were weighed and handled for several 
minutes per day to get familiarized to handling by the investigator. All procedures were 
approved by the Institutional Animal Care Committee and followed the Canadian and 
National Institute of Health Guides for the Care and Use of Laboratory Animals (NIH 
Publication #80-23). 
 Drugs 
The glutamate NMDA receptor antagonist MK-801 [(+)-MK-801 maleate, MWt: 
337; (dizocilpine); 0.075 mg/kg or 0.05 mg/kg of the salt form; Sigma-Aldrich, St. 
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Louise, MO], and dopamine D1 antagonist SCH 23390 [(R)-(+)-SCH 23390 
hydrochloride, MWt: 324; 0.005 mg/kg of the salt form; Sigma-Aldrich] were used, with 
the doses chosen based on pilot studies. Despite a small difference in concentration (0.18 
on a Log10 scale), 0.075 mg/kg of MK-801 consistently affected set-shifting compared to 
0.05 mg/kg dose in pilot studies. Thus, in the present study, these doses of MK-801 were 
employed and referred to as “effective” and “behaviourally sub-effective” doses, 
respectively. Drugs were freshly prepared and dissolved in physiological saline. Rats 
received subcutaneous injections of drugs individually or in combination on the day of 
response discrimination (i.e., set-shifting), 25 min prior to the visual-cue retrieval trials. 
In pilot studies, higher doses of SCH 23390 resulted in gross motor deficits, which 
rendered animals incapable of performing the visual-cue and set-shifting tasks, and 
therefore, experiments using these higher doses of SCH 23390 were not included in the 
present study. 
 Apparatus 
The operant conditioning apparatus (Med-Associates, St. Albans, VT, USA) 
consisted of a modular acrylic test chamber (30.5 X 24 X 21 cm), housed in a sound-
attenuating box. The test chamber was equipped with grid floor, two retractable levers on 
either side of a central pellet receptacle, and a house light (white, 100-mA, located 
centrally on the top of the wall opposite to the levers). Positioned above each lever was a 
cue light (light emitting diode). Following a lever-press that was considered a correct 
response, a pellet dispenser dropped a sucrose pellet (45 mg; BioServ, Frenchtown, NJ) 
into the central pellet receptacle. The operation of the chamber was controlled by a 
customized computer software program (MED-PC IV, Med-Associates).  
 Set-shifting  
Behavioural flexibility was assessed in rats using an operant conditioning-based a 
set-shifting task developed by Floresco et al. (2008), with minor modifications. As 
described in detail below, rats were exposed to a series of experimental steps which 
included acclimatization to the chamber, training to press the levers, determination of the 
rat’s preference for one lever over the other (i.e., its side bias), visual-cue discrimination 
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ability, and finally, response discrimination ability to assess behavioural flexibility. Each 
rat completed this entire series of experimental steps only once. 
2.3.4.1 Acclimatization 
Rats were given 10 sucrose pellets in their home cage a day before their first 
exposure to the operant chamber. On the acclimatization day, rats were given 3 sucrose 
pellets in the receptacle as well as 3 crushed pellets were placed on the extended lever. 
Once the rat learned the relationship between lever-pressing and reinforcement, it had to 
achieve the criterion of 30 lever presses in 50 min. Once achieved, the second lever was 
inserted into the chamber, and the first lever was retracted. After achieving the 
performance criterion for both levers, rats were ready for the training procedure (Please 
see Figure 2.1 for timeline of experiments). 
2.3.4.2 Training 
On the training day, a trial began with illumination of the house light, and the 
random insertion of one of the retracted levers into the chamber. Rats were given 10 s to 
respond on the extended lever. If the rat pressed the extended lever, a sucrose pellet 
(reinforcement) was dispensed in the central receptacle, and the house light remained on 
for an additional 4 s (reward length). If the rat failed to respond within 10 s, the house 
light was turned off, the lever was retracted without pellet reinforcement, and the trial 
was counted as an omission. Each training trial lasted 20 s. Over a total of 90 successive 
trials, each of the levers was randomly inserted into the chamber, and the performance 
criterion set was less than 5 omissions. 
2.3.4.3 Side bias determination  
Once the rats achieved the criterion for the training session, their side bias was 
determined on the same day. A side bias trial began with the illumination of the house 
light and the insertion of both levers into the chamber. Rats were given 10 s to respond on 
either of the levers. Upon pressing one of the levers, both levers were then retracted, a 
pellet reinforcement was delivered, and the house light remained on for an additional 4 s 
before the chamber went dark. If the rat failed to respond within 10 s, the house light was 
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turned off, the levers were retracted without pellet reinforcement, and the trial was 
counted as an omission. The next trial began with the illumination of the house light and 
the insertion of both levers into the chamber, but this time the rat was given 10 s to 
respond on the lever opposite to its initial choice. If rat responded correctly, a pellet 
reinforcement was given. If rat pressed the wrong (i.e, initial) lever, both levers were 
retracted, reinforcement was not delivered, and the chamber went dark. This continued 
until rat responded on correct lever. In total, seven complete trials were conducted (i.e., 
initial choice and correct second choice). For each rat, the lever that was pressed as the 
initial choice more often was considered its side bias. This preference was acknowledged 
on the response discrimination day (set-shift day), where the lever opposite to the rat’s 
side bias was always considered the correct lever. 
2.3.4.4 Visual-cue discrimination 
On the day following training and side bias determination, rats were subjected to a 
visual-cue discrimination task where they had to follow the cue light as a strategy to 
receive pellet reinforcement. A trial started with random illumination of one of the cue 
lights. After 3 s, the house light was turned on, and both the levers were extended into the 
chamber. The rat was given 10 s to respond on the lever positioned under the illuminated 
cue light. If the rat chose the correct lever, a pellet reinforcement was offered, both levers 
were retracted, the house light remained on for 4 s, and the trial was counted as a correct 
response. Pressing the wrong lever resulted in retraction of both levers, no pellet 
reinforcement being offered, and the chamber going dark. The performance criterion 
established for visual-cue discrimination was 10 consecutive correct responses, and the 
maximum number of trials performed was 100. We modified the original procedure 
developed by Floresco et al. (2008) by having all rats complete 100 trials instead of 
ending the session at the moment when a given rat achieved the performance criterion.  
2.3.4.5 Response discrimination 
On the day after visual-cue discrimination, rats were injected with drugs or 
vehicle in their home cage, and 25 min later, they were subjected to 20 visual-cue 
discrimination trials to determine the effect of drug treatments on retrieval of the memory 
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and motor function to perform the expected task. On the 21st trial, the paradigm was 
switched from a visual-cue discrimination to a response discrimination, in which the rats 
had to abandon the original rule (i.e., follow the cue light) and adopt a new rule which 
was previously irrelevant (i.e., lever side). During set-shifting, rats had to respond on the 
lever opposite to their side bias during every trial regardless of the location of the visual-
cue. A trial started with random illumination of one of the visual-cue lights. After 3 s, the 
house light turned on, both levers were extended into the chamber, and the rat was given 
10 s to respond on the lever opposite to its side bias. If the rat responded on the correct 
lever, a pellet reinforcement was delivered, both levers were retracted, the house light 
stayed for an additional 4 s, and the trial was counted as a correct response. Pressing the 
wrong lever was counted as an error, resulting in retraction of both levers, no pellet 
reinforcement being offered, and the chamber going dark. The response discrimination 
session ended when either the rat made 10 consecutive correct responses or if the 
maximum number of 120 trials was performed. Total number of trials taken and errors 
committed to achieve criterion were recorded. 
2.3.4.6 Error analysis 
Errors committed during set-shifting (response discrimination) were divided into 
three different categories according to Floresco et al. (2008): perseverative error, 
regressive error and never-reinforced error. An error was called “perseverative” or 
“regressive” if during the set-shifting, the rat responded on the lever associated with 
visual-cue light when it was required to press the opposite lever to receive the pellet 
reinforcement. In a block of 16 trials, 8 of the trials required the rat to respond on the 
lever opposite to the visual-cue light. During those 8 trials, if the rat committed errors by 
pressing the lever associated with visual-cue light in 6 or more trials, all the errors 
committed in that block were considered “perseverative” errors. In contrast, if the rat 
made the same error in 5 or less number of trials, now all of these errors in the particular 
block were referred to as “regressive” errors. A “never-reinforced error” occurred during 
a trial when the visual-cue light was associated with the correct lever, yet the rat 
responded on opposite lever; a situation that had never been positively reinforced in 
either the visual-cue or response discrimination task.  
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2.3.4.7 Possible effect of combined drug treatment on learning 
A separate experimental series was conducted on naïve rats in order to determine 
whether the combined treatment of MK-801 (0.05 mg/kg) and SCH 23390 (0.005 mg/kg) 
affected learning of a given lever-pressing rule, as opposed to actual set-shifting. One day 
after being trained to press the levers, these rats (n=5 per group) were administered 
systemically with either vehicle (saline) or the combined treatment of MK-801 (0.05 
mg/kg) and SCH 23390 (0.005 mg/kg), and 25 min later, tested on their ability to learn 
the visual-cue discrimination task. Because this was the first time that these rats had been 
exposed to the visual-cue discrimination task, this experiment would determine if the 
combined administration of the behaviourally sub-effective doses of MK-801 and SCH 
23390 caused a general inability to learn a lever-pressing rule, separate from the 
behavioural flexibility necessary to perform set-shifting. These rats did not go on to 
perform a subsequent response discrimination (i.e., set-shifting) experiment the next day. 
 Statistical analysis 
All animals included in the analysis of response discrimination showed 
comparable performance in visual-cue discrimination on the previous day to ensure 
similar baseline function. A one-way analysis of variance (ANOVA) was employed to 
compare effect of drug treatments on visual-cue retrieval, trials and errors to criteria, and 
number of omissions. For type of errors and latency, a two-way mixed ANOVA was 
used. Results of visual-cue learning was analyzed using student’s two-tailed t-test. All 
statistical analyses were conducted with  = 0.05 using GraphPad Prism 7.0 software. 
Following ANOVA, significant values were further analyzed using the Tukey’s post hoc 
test. All data are presented as mean  standard error of mean (SEM). 
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Figure 2.1 Timeline of set-shifting task. 
Following handling and acclimatization to the chamber, the rats were subjected to 
training. Once the rats achieved the criterion for the training session, their side bias 
was determined on the final day of training. On the next day, rats were subjected to 
visual-cue discrimination, and the following day was the response discrimination (set-
shifting) test. On the response discrimination day, the rats were injected with drugs or 
vehicle, and 25 min later, they were subjected to 20 visual-cue discrimination trials to 
determine the effect of drug treatments on retrieval of the memory and motor function. 
On the 21st trial, the paradigm was switched from a visual-cue discrimination to a 
response discrimination that lasted until either the rat made 10 consecutive correct 
responses or to the maximum number of 120 trials. 
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2.4 Results  
 Effect of MK-801, SCH 23390 or combined drug treatment on 
visual-cue retrieval  
In order to determine whether administration of MK-801 and/or SCH 23390 
produced any noticeable effect on memory retrieval or motor performance, rats were 
subjected to 20 trials of visual-cue discrimination just prior to the response discrimination 
(i.e., set-shifting) trials. Results showed that none of the drugs at the chosen doses 
affected the performance of visual-cue retrieval on the day of response discrimination 
(Figure 2.2; P>0.05, One-way ANOVA).  
  
Figure 2.2 Effect of systemic administration of individual or combined antagonists on 
visual-cue retrieval on set-shift day. 
On the set-shift day (response discrimination day), treatment with MK-801(0.05 or 0.075 
mg/kg; s.c.), SCH 23390 (0.005 mg/kg; s.c.) or the combination of MK-801 (0.05 mg/kg; 
s.c.) and SCH 23390 (0.005 mg/kg; s.c.) did not affect visual-cue retrieval indexed by the 
unchanged number of errors committed during the first 20 visual-cue trials as compared to 
the vehicle group (P>0.05, One-way ANOVA). 
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 Effect of MK-801, SCH 23390 or combined drug treatment on set-
shifting  
2.4.2.1 Number of trials to criterion  
 Rats were administered with individual antagonists (n=7, each group) or a 
combination of behaviourally sub-effective doses of antagonists (n=7) 25 min prior to the 
visual-cue retrieval trials on the day of the set-shifting test. Injections of MK-801 (0.075 
mg/kg; s.c.) significantly increased the total number of trials to criterion 
[F(4,30) = 15.80, P<0.05] compared to the vehicle-treated group (Figure 2.3; one-way 
ANOVA followed by the Tukey’s post hoc test). Thus, the 0.075 mg/kg dose of MK-801 
when administered systemically, significantly impaired set-shifting in rats. On the other 
hand, MK-801 at the lower dose tested (0.05 mg/kg; s.c.) did not show any change in the 
number of trials to criterion (P>0.05), and therefore, this dose was considered to be 
“behaviourally sub-effective.” Similarly, SCH 23390 (0.005 mg/kg) did not significantly 
affect trials to criterion as compared to the vehicle-treated group (P>0.05), hence, this 
dose was deemed to be behaviourally sub-effective. In pilot studies, rats that received 
higher doses of SCH 23390 (0.01 or 0.02 mg/kg; s.c.) experienced noticeable motor 
deficits and increased response latency, which resulted in a significant number of 
omissions in both the visual-cue retrieval and set-shifting trials, and ultimately a failure to 
complete the sessions (data not shown). 
  Administration of a combination of the behaviourally sub-effective doses of MK-
801 (0.05 mg/kg; s.c.) and SCH 23390 (0.005 mg/kg; s.c.) significantly increased the 
number of trials to criterion [F(4,30) = 15.80, P<0.05]. Tukey’s post hoc test revealed 
that the combined treatment increased the number of trials to criterion significantly more 
than vehicle treatment as well as the separate injections of the behaviourally sub-effective 
doses of MK-801or SCH 23390 (P<0.05). Interestingly, the effective (higher) dose MK-
801 (0.075 mg/kg; s.c.) group did not differ from the group that received the combined 
treatment of behaviourally sub-effective doses of MK-801 and SCH 23390 in the number 
of trials to criterion (P>0.05).  
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Figure 2.3 Effect of systemic administration of individual or combined antagonists 
on trials to criterion during set-shifting. 
Low dose MK-801 (0.05 mg/kg; s.c.) or SCH 23390 (0.005 mg/kg; s.c.) did not affect the 
number of trials to criterion as compared to the vehicle group (P>0.05), and as such, 
these doses were considered to be “behaviourally sub-effective.” Alternatively, the 
higher dose MK-801(0.075 mg/kg; s.c.) significantly increased the number of trials to 
criterion during set-shifting as compared to the vehicle, low dose MK-801 (0.05 mg/kg; 
s.c.), and SCH 23390 (0.005 mg/kg; s.c.) groups (*P<0.05). Consistent with our working 
hypothesis, the combined administration of the behaviourally sub-effective doses of MK-
801 (0.05 mg/kg; s.c.) and SCH 23390 (0.005 mg/kg; s.c.) significantly increased the 
number of trials to criterion as compared to the vehicle group and the individual 
treatment groups of either low dose MK-801 (0.05 mg/kg; s.c.) or SCH 23390 (0.005 
mg/kg; s.c.) (*P<0.05). Finally, the combined antagonist treatment group did not show 
significant change in the number of trials to criterion as compared to the higher dose 
MK-801 (0.075 mg/kg; s.c.) group (P>0.05). [One-way ANOVA followed by Tukey’s 
post hoc test]. 
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2.4.2.1 Number of errors to criterion  
  Injections of MK-801 (0.075 mg/kg; s.c.) significantly increased the total number 
of errors committed during the set-shifting [F(4,30) = 14.67, P<0.05] as compared to the 
vehicle-treated group (Figure 2.4; one-way ANOVA followed by the Tukey’s post hoc 
test). On the other hand, lower dose of MK-801 (0.05 mg/kg; s.c.) did not affect errors to 
criterion P>0.05. Likewise, SCH 23390 (0.005 mg/kg) did not significantly influence 
number of errors committed during the set-shifting as compared to the vehicle-treated 
group (P>0.05), hence, this dose was considered to be “behaviourally sub-effective”. 
  Combined administration of behaviourally sub-effective doses MK-801 (0.05 
mg/kg; s.c.) + SCH 23390 (0.005 mg/kg) significantly increased number of errors 
committed during set-shifting [F(4,30) = 14.67, P<0.05]. Tukey’s post hoc analysis 
showed a significantly increased (P<0.05) number of errors to criterion following the 
combined treatment in comparison to vehicle treatment or separate antagonist injections. 
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Figure 2.4 Effect of systemic administration of individual or combined antagonists on 
errors to criterion during set-shifting. 
Similar to the trials to criterion, the number of associated errors made during the set-
shifting session showed comparable treatment effects. As predicted, the number of errors 
to criterion was found to be increased significantly following the combined administration 
of MK-801 (0.05 mg/kg) and SCH 23390 (0.005 mg/kg) as compared to the vehicle group 
and the individual treatment groups of either MK-801 (0.05 mg/kg) or SCH 23390 (0.005 
mg/kg) (*P<0.05). In contrast, the combined antagonist treatment group did not show 
significant change in the number of errors to criterion as compared to the higher dose MK-
801 (0.075 mg/kg) group (P>0.05). Consistent with the combined antagonist treatment 
group, the higher dose MK-801 (0.075 mg/kg) treatment significantly increased the 
number of errors committed during the set-shifting session as compared to the vehicle, 
low dose MK-801 (0.05 mg/kg) or SCH 23390 (0.005 mg/kg) group (*P<0.05). [One-way 
ANOVA followed by Tukey’s post hoc test]. 
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2.4.2.2 Type of errors 
In accordance with Floresco et al. (2008), the errors committed during set-shifting 
trials were classified into three different types: perseverative, regressive and never-
reinforced (see Methods for details). Errors were analyzed using two-way mixed 
ANOVA, as described previously in studies using a similar paradigm (Bornstein et al., 
1990; Ishikawa et al., 2004; Szoke et al., 2008). Whenever significant interactions 
between the treatment conditions and the type of errors were found, the data were further 
analyzed using Tukey’s post hoc test. Significant effects were observed for perseverative 
errors in the between-subject factor (treatment) [F(4,24) = 16.94, P<0.05] as well as 
within-subject factor (type of errors) [F(2,12) = 113.3, P<0.05]. Tukey’s post hoc test 
revealed a significant difference (P<0.05) between perseverative errors committed by the 
group treated with combination of antagonists versus the control group, low dose MK-
801 (0.05 mg/kg) or SCH 23390 (0.005 mg/kg). A significant interaction between 
treatment X type of errors was also observed [F(8,48) = 2.36, P<0.05] (Figure 2.5). The 
number of perseverative errors committed by the combined treatment group and effective 
(higher) dose MK-801 (0.075 mg/kg; s.c.) group were not significantly different 
(P>0.05). Compared to the control group, none of the treatments affected regressive or 
never-reinforced errors (P>0.05).   
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Figure 2.5 Effect of drug treatments on different type of errors committed during set-
shifting. 
The combined administration of the behaviorally sub-effective doses of MK-801 (0.05 mg/kg) and 
SCH 23390 (0.005 mg/kg) resulted in a significant increase in the number of perseverative errors 
as compared to the vehicle group and the individual treatment groups of either MK-801 (0.05 
mg/kg) or SCH 23390 (0.005 mg/kg) (*P<0.05). Similarly, the higher dose MK-801 (0.075 
mg/kg) treatment significantly increased perseverative errors as compared to the vehicle, low dose 
MK-801 (0.05 mg/kg) or SCH 23390 (0.005 mg/kg) groups (*P<0.05). Animals that received the 
combined antagonist treatment did not differ significantly from higher dose MK-801 (0.075 
mg/kg) treated rats in any type of error (P>0.05). Finally, none of the treatments significantly 
increased the number of regressive or never-reinforced errors beyond those made by the vehicle 
group. All drugs were administered s.c. [two-way mixed ANOVA followed by Tukey’s post hoc 
test]. 
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 Response latencies 
Because our pilot studies using higher doses of SCH 23390 (0.01 or 0.02 mg/kg; 
s.c.) revealed noticeable motor deficits that ultimately impaired performance, in the 
present study we compared the latencies of response on the extended levers for last 5 
trials of the different trial types: i) correct response on non-perseverative trials, ii) correct 
response on trials where a perseverative error was possible, and iii) perseverative error 
trials. A two-way ANOVA revealed that latencies for all the groups were similar for all 
three trial types (P>0.05) (Figure 2.6). These data suggest that motor function was not 
affected by the various treatments. 
 
 
 Omissions 
The number of omissions made during response discrimination trials was 
determined for all of the groups. Occurrence of omissions was negligible in all the groups 
tested (P>0.05; One-way ANOVA) (Figure 2.6). 
  
Figure 2.6 Effect of drug treatments on latencies to response during different types of 
trials.  
During each trial, animals were given 10 s to press one of the extended levers. As compared 
to the vehicle group (P>0.05; Two-way ANOVA), none of the treatments showed significant 
change in latencies to response during the various trial types: i) Correct non-perseverative: A 
correct choice on a trial where there is no possibility of making a perseverative error; ii) 
Correct perseverative chance: A correct response on a trial where a perseverative error is 
possible; and iii) Perseverative error: An incorrect choice on a trial where a perseverative 
error is possible. All drugs were administered s.c. in mg/kg doses as shown.  
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 Omissions 
A one-way ANOVA revealed that number of omissions committed during set-
shifting were comparable across all the groups (P>0.05) (Figure 2.7). These data suggest 
that motor function was not affected by the various treatments. 
 
 
 
  
Figure 2.7 Effect of drug treatments on number of omissions committed during 
set-shifting. 
None of the treatments significantly changed the number of omissions committed 
during set-shifting as compared to the vehicle group (P>0.05; One-way ANOVA). All 
drugs were administered s.c. in mg/kg doses as shown. 
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2.5 Discussion 
The main finding of the present study was that the combined systemic 
administration of relatively low doses of glutamate NMDA and dopamine D1 receptor 
antagonists which were found to be ineffective at altering behavioural performance when 
injected separately caused a significant impairment in set-shifting in rats performing an 
operant conditioning-based task. To our knowledge, this is the first pharmacological 
evidence of an interaction between glutamate and dopamine systems in regulating 
executive function. 
 Our results also showed that the impairment of set-shifting ability produced by the 
combination of behaviourally sub-effective doses of NMDA and D1 antagonists is 
associated with increased perseverative errors, whereas the occurrence of regressive or 
never-reinforced errors was unaffected. Perseverative errors occur when participants 
cannot disengage from their adherence to a previously correct rule, despite prompt 
negative feedback that a new strategy is warranted. Previous preclinical models have 
shown that inactivation of the mPFC or mediodorsal thalamus results in increased 
perseverative errors (Block et al., 2007; Floresco et al., 2008; Parnaudeau et al., 2015). 
On the contrary, regressive errors occur after participants have been able to temporarily 
disengage from the now-incorrect rule/strategy, yet they are unable to maintain the new 
strategy despite receiving positive feedback. Unlike perseveration, inactivation of brain 
structures including the striatum and nucleus accumbens core have been shown to cause 
increased regressive errors (Block et al., 2007; Floresco et al., 2009). Perseverative errors 
may result from failure in high-order cognitive flexibility, whereas regressive errors may 
result from deficits in sustained attention (Sullivan and Faust, 1993; Hughes et al., 1997; 
Russell et al., 1999; Ozonoff et al., 2004).  
 Increased perseverative error is a consistent finding in schizophrenia patients 
performing the WCST (Bornstein et al., 1990; Szoke et al., 2008; Waford and Lewine, 
2010), and it was also proposed as an endophenotype as unaffected siblings of 
schizophrenia patients show high degree of perseverative errors in the WCST (Saoud et 
al., 2000). Evidence, however, indicates that increased number of perseverative errors in 
the WCST is also seen in non-psychotic patients diagnosed with bipolar disorder, major 
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depression or autism (Rempfer et al., 2006; Griebling et al., 2010; Waford and Lewine, 
2010; Landry and Al-Taie, 2016). Our results show that a combined systemic 
administration of NMDA and D1 receptor blockers, at doses that do not cause 
behavioural effects when these antagonists were administered separately, results in 
increased incidence of perseverative errors. Based on the findings in the present study, it 
is reasonable to suggest that subtle functional decreases in glutamate and dopamine 
neurotransmission in circuits sub-serving successful performance of the WCST may act 
cooperatively to manifest perseverative errors in the above-listed neuropsychiatric 
disorders.  
   Interestingly, the extent of impairment and error profile seen following systemic 
administration of behaviourally sub-effective doses of NMDA and D1 antagonists are 
similar to that seen following administration of the effective (higher) dose of MK-801. 
This may suggest that the addition of the D1 antagonist may exacerbate the NMDA 
functional deficit in certain brain circuitries. It is also important to note that although 
SCH 23390 has been shown to block dopamine D5 and serotonin 5HT2A receptors, the 
dose of SCH 23390 used in the present study may have blocked D5 receptors but not 
5HT2A (Suhara et al., 1992; Emmi et al., 1997). Interactions between NMDA receptors 
and D1 receptors has been described in several brain areas (Greengard, 2001; Chen et al., 
2004; Tong and Gibb, 2008; Wigestrand et al., 2012). Acting on the same postsynaptic 
profile, dopamine affects the second messenger systems and protein phosphorylation 
through D1 receptors to facilitate NMDA receptor function (Greengard, 2001). In 
addition, a direct receptor-receptor interaction also has been observed between NMDA 
and D1 receptors in the rat (Lee et al., 2002; Martina and Bergeron, 2008). More 
importantly, a recent study found that SCH 23390 induced a dose-dependent decrease of 
[3H]MK-801 binding to membranes from rat hippocampus indicating a direct interaction 
between SCH 23390 and MK-801 (Wigestrand et al., 2012). Considering that increased 
perseverative errors have been observed following manipulation of either the mPFC, 
mediodorsal thalamus or hippocampus (Block et al., 2007; Enomoto et al., 2011; Shaw et 
al., 2012), and the present study used systemic injections of antagonists, it is possible that 
the interaction between NMDA and D1 receptors indicated by our results may not 
necessarily occur in the same neuron or even in the same brain area. Further studies are 
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needed to identify the precise brain regions and neuronal connections where relatively 
low doses of MK-801 and SCH 23390 exert their actions to cause perseverative errors. It 
is also possible that these antagonists might have affected different components of 
executive function to certain degree and these effects when combined become sufficient 
to affect the set-shifting performance. 
  Previous preclinical studies have shown that direct infusion of either dopamine 
D1 or NMDA receptor antagonists into the mPFC in rats resulted in disrupted set-shifting 
and increased perseverative errors (Stefani et al., 2003; Fletcher et al., 2005; Floresco et 
al., 2006). Similar to the mPFC, dopamine D1 receptor activity in the core region of the 
nucleus accumbens has been found to be essential for set-shifting (Floresco et al., 2009; 
Haluk and Floresco, 2009). Pharmacological or designer receptors exclusively activated 
by designer drugs (DREADD)-mediated inactivation of mediodorsal thalamic nuclei that 
send reciprocal glutamatergic projections to the prefrontal cortex resulted in impaired set-
shifting and increased occurrence of perseverative errors (Block et al., 2007; Parnaudeau 
et al., 2015) indicating a potentially important role for glutamatergic activity in the 
mediodorsal thalamus and its prefrontal cortical connection in executive function. As 
mentioned, abnormalities in the prefrontal cortex, nucleus accumbens and the 
mediodorsal thalamus are consistently reported in post-mortem and in vivo imaging 
studies of schizophrenia. Consequently, we elected to use systemic injections to 
antagonize D1 and/or NMDA receptors. Despite sacrificing brain regional specificity for 
the site of action of these antagonists, our approach allowed us to assay several brain 
areas that are not only relevant to executive function but also might have abnormalities in 
dopamine D1 and NMDA receptor function contributing to executive functional deficits 
of schizophrenia. Overall, our choice to use systemic injections of the D1 and NMDA 
receptor antagonists in the present study is consistent with comments made in a review by 
Floresco et al. (2009), which stated that, “…a more complete understanding of the 
mechanisms underlying impaired flexibility in schizophrenia may be obtained from the 
elucidation of dysfunction that occurs in these cortical-subcortical circuits, rather than 
focusing on disruptions in functioning of the prefrontal cortex or subcortical systems 
alone”.  
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2.6 Conclusions  
Despite the prevailing notion that schizophrenia is associated with severe 
neurochemical and synaptic disturbances in several brain areas and circuitries based on 
post-mortem findings, recent in vivo neuroimaging studies provide a contradictory view 
in which the neurotransmitter abnormalities in the brains of patients living with 
schizophrenia appear to be quite subtle. Consequently, it may be more difficult than 
anticipated to draw sufficient parallels between these neuroimaging studies and the 
previous preclinical models of behavioural flexibility which induced significant 
pharmacological disruption of a given neurotransmitter/receptor system. In considering 
the potential for subtle disturbances in multiple neurotransmitter systems in 
schizophrenia, we investigated the consequence of combining acute systemic injections 
of D1 receptor and NMDA receptor antagonists on behavioural flexibility in normal adult 
rats as assessed with an operant conditioning based set-shifting task. Our results show 
that behaviourally sub-effective doses of D1 and NMDA receptor antagonists cooperate 
synergistically to cause disruption of set-shifting which is characterized by an increase 
the occurrence of perseverative errors.  
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Chapter 3  
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 Glutamate and dopamine abnormalities in the medial 
prefrontal cortex act synergistically to cause executive 
dysfunction  
3.1 Abstract  
Impairment of executive function is a core feature of schizophrenia, with patients 
showing perseverance in tasks requiring behavioural flexibility. Abnormalities in 
dopaminergic and glutamatergic neurotransmission within the prefrontal cortex have 
been implicated in schizophrenia, and preclinical models have confirmed the importance 
of these neurotransmitter systems in behavioural flexibility. The present study 
investigated whether intra-medial prefrontal cortex (mPFC) co-infusion of dopamine D1 
and glutamate N-Methyl-D-aspartic acid (NMDA) receptor antagonists at sub-effective 
doses affect behavioural flexibility. Male Sprague-Dawley rats received bilateral intra-
mPFC infusion of the dopamine D1 antagonist, SCH 23390, and the NMDA 
uncompetitive antagonist, MK-801, at various doses, either alone or in combination prior 
to performance of a lever-pressing set-shifting task. Task performance was sensitive to 
the doses infused into the mPFC; the higher doses of antagonists (0.05 μg/side SCH 
23390; 0.25 μg/side MK-801) each impaired set-shifting, whereas the separate infusion of 
the lower doses (0.025 μg/side SCH 23390; 0.125 μg/side MK-801) was ineffective. As 
predicted, the co-infusion of these lower doses significantly increased the number of 
trials needed to complete the task and the number of perseverative errors committed, 
while not affecting learning or memory retrieval. The synergistic effect of SCH 23390 
and MK-801 on set-shifting performance confirmed that behavioural flexibility depends 
on coincident activation of mPFC dopamine D1 and glutamate NMDA receptors. The 
collective results support the suggestion that perseverance can manifest from a subtle 
disruption in both dopaminergic and glutamatergic neurotransmission within the mPFC; 
findings which are relevant for studies attempting to model schizophrenia 
pathophysiology.  
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3.2 Introduction 
Executive function, comprising cognitive processes such as working memory, 
attention and behavioural flexibility, enables us to solve problems, form strategies, and 
adapt to unexpected conditions to achieve goals (Orellana and Slachevsky, 2013; 
Rowland et al., 2013). Deficits in executive function are associated with a range of 
disorders, including Alzheimer’s disease, attention deficit hyperactivity disorder 
(ADHD), and schizophrenia (Elliott, 2003). For example, patients with schizophrenia 
show difficulties in inhibiting a previously-learned strategy (i.e., they make perseverative 
errors) during performance of the Wisconsin card sorting test (WCST)-a 
neuropsychological assessment requiring behavioural flexibility (Bornstein et al., 1990; 
Braff et al., 1991; Rosse et al., 1991; Abbruzzese et al., 1996; Perry and Braff, 1998; 
Gooding et al., 1999; Everett et al., 2001; Prentice et al., 2008; Waford and Lewine, 
2010; Orellana and Slachevsky, 2013). Based on the findings from functional 
neuroimaging studies in healthy subjects as well as patients with schizophrenia, it is well 
established that the dorsolateral prefrontal cortex (dlPFC) contributes to the successful 
performance of the WCST (Weinberger et al., 1986; Andreasen et al., 1990; Berman et 
al., 1995; Nagahama et al., 1996; Fletcher et al., 1998; Callicott et al., 2000; Monchi et 
al., 2001; Passingham and Wise, 2014; Boschin et al., 2017). Similarly, preclinical 
studies in rodents have identified the role of the medial prefrontal cortex (mPFC) in 
executive function, as lesioning/inactivating this brain region causes impairments in 
working memory (Ragozzino et al., 2002b; Yoon et al., 2008; O’Neill et al., 2013; Liu et 
al., 2014), decision making (Sul et al., 2010; Euston et al., 2012; Lee and Seo, 2016) and 
set-shifting (i.e., the shifting of attention from one stimulus dimension to another) 
(Ragozzino et al., 1999, 2002a; Birrell and Brown, 2000; Block et al., 2007; Ragozzino, 
2007; Floresco et al., 2008). Consistent with the deficits in set-shifting observed in 
patients with schizophrenia, altered activity in the mPFC has been shown to cause 
increased perseverance in rodent models (Birrell and Brown, 2000; Ragozzino, 2002a; 
Stefani and Moghaddam, 2005; Block et al., 2007; Floresco et al., 2008; Enomoto et al., 
2011). 
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 Preclinical models have also confirmed the importance of dopaminergic and 
glutamatergic neurotransmission within the mPFC in behavioural flexibility, as intra-
mPFC infusion of individual D1 and NMDA receptor antagonists can impair 
performance during set-shifting (Ragozzino et al., 2002a; Stefani et al., 2003; Stefani and 
Moghaddam, 2005; Gauthier et al., 2014). In addition, we recently reported an increased 
perseverance in rats following the systemic co-administration of dopamine D1 and 
NMDA receptor antagonists at doses that were low enough to be ineffective at altering 
set-shifting when injected separately (Desai et al., 2017). Because these “behaviourally 
sub-effective” doses were injected systemically, it was not possible to conclude whether 
this synergistic effect of antagonists on behavioural flexibility was mediated directly 
through coincident deactivation of dopamine D1 and NMDA receptors within the mPFC. 
That said, it is reasonable to predict that set-shifting could be impaired due to local mPFC 
disruption of both the dopaminergic and glutamatergic neurotransmitter systems because 
dopamine D1 and NMDA receptors are co-localized on pyramidal neurons and 
interneurons within the PFC, and activation of these D1 receptors potentiates NMDA-
mediated calcium responses (Kruse et al., 2009). In further support of our working 
hypothesis, a previous study on rats found that repetitive co-infusion of low, individually-
ineffective doses of dopamine D1 and NMDA receptor antagonists into the mPFC 
disrupted instrumental learning over a multi-day lever-pressing task (Baldwin et al., 
2002).  
 To determine if behavioural inflexibility requires coincident blockade of 
dopamine D1 and NMDA receptors within the mPFC, we exposed rats to bilateral intra-
mPFC infusion of the dopamine D1 antagonist, SCH 23390, and the NMDA 
uncompetitive antagonist, MK-801, at various doses, either alone or in combination prior 
to performance of a set-shifting task. Here, we report for the first time that the combined 
infusion of these antagonists at doses that failed to impair performance when injected 
alone ultimately resulted in increased perseverance; findings which support the 
suggestion that a mild disruption in both dopaminergic and glutamatergic 
neurotransmission within the mPFC is sufficient to cause significant impairment in 
behavioural flexibility. 
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3.3 Materials and methods 
 Animals 
Fifty-six adult male Sprague-Dawley adult rats were used in this study (Charles 
River, Quebec, Canada). All rats were kept in a facility with temperature- and humidity-
controlled rooms (24±2 °C, relative humidity 55±10%), where they were maintained on a 
12-h light/dark cycle (lights on at 7:00 am). In preparation for behavioural training, rats 
were food restricted up to 85-87% of their free feeding body weight, and they were 
handled for approximately five minutes per day to get familiarized to the investigator. 
During the last couple of days of food restriction, rats were given five sucrose pellets (45 
mg; BioServ, Frenchtown, NJ, USA) in their home cage so that they could become 
familiar with the pellets used as a positive reinforcement in the behavioural tasks. 
 Drugs 
 The glutamate NMDA receptor uncompetitive antagonist (+) MK-801 
(dizocilpine hydrogen maleate) and dopamine D1 antagonist (R)-(+) SCH 23390 
hydrochloride were obtained from Sigma-Aldrich (St. Louis, MO, USA), and dissolved 
in sterile saline to achieve the following concentrations: MK-801 (0.125 and 0.25 g/0.5 
L) and SCH 23390 (0.025 and 0.05 g/0.5 L). The doses of both antagonists were 
based upon their salt form. Fresh solutions were prepared on the day of infusion, and 
stored in a refrigerator. All infusions were made with solutions at room temperature. 
 Surgery 
 Rats were anesthetized with isoflurane (Forene®, Baxter Corporation, 
Mississauga, ON, Canada), mounted in a stereotaxic frame, and injected with metacam 
(Boehringer Ingelheim, Burlington, ON, Canada) and an antibiotic (Baytril®, Bayer Inc., 
Toronto, ON, Canada). For intra-mPFC drug infusion, bilateral guide cannulae (27 G, 2 
mm length; RWD Life Science Inc., San Diego, CA, USA) were implanted using 
stereotaxic coordinates to target the prelimbic cortex (relative to bregma: AP= + 3.24, 
ML= ± 0.8, DV= −1.5 mm from skull surface; Paxinos and Watson, 2007). These guide 
cannulae were secured to the skull with four screws and dental cement. Stainless steel 
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dummy cannulae were inserted in the guide cannulae to prevent clogging prior to the 
micro-infusion, which occurred several days later. Rats were allowed at least six days of 
recovery from surgery before initiation of the food restriction. Over this period, rats were 
handled daily during various procedures, including general holding, weighing and 
cleaning of dummy cannulae.  
 Micro-infusion procedure 
Intra-mPFC injections were performed in awake animals using infusion cannulae 
that extended 2 mm beyond the length of the guide cannulae. On the experimental day, 
rats received bilateral infusion of either the dopamine D1 receptor antagonist SCH 23390 
(0.025 μg or 0.05 μg /0.5 μL/side), the uncompetitive NMDA receptor antagonist MK-
801 (0.125 μg or 0.25 μg /0.5 μL/side) or 0.9% sterile saline as vehicle (0.5 μL/side) into 
the prelimbic region of the mPFC 7 min before the beginning of the set-shifting session 
(Experiment 1) or the visual-cue learning paradigm (Experiment 2 Figure 3.1). In animals 
that received the combination of SCH 23390 and MK-801, appropriate doses of these 
antagonists were infused in a volume of 0.5 μL on each side. Both sides were infused 
simultaneously using a microinfusion pump and Hamilton syringes connected to the 
infusion cannula via Teflon tubing. Infusion were made over 5 min (0.1 μL/min), and the 
infusion cannulae were then left in place for an additional 2 min to allow adequate 
diffusion of the drug into the surrounding brain tissue. 
 Behavioural apparatus 
Behavioural training and testing were performed in an operant conditioning 
apparatus, which included a modular acrylic test chamber (30.5 x 24 x 21 cm), housed in 
a sound-attenuating box. On the front wall of the test chamber were two stimulus lights, 
each located above a retractable lever that was positioned on either side of a central pellet 
receptacle. A house light was located on the back wall of the chamber. The chamber was 
controlled by a customized computer software program (MED-PC IV, Med-Associates). 
For example, when the rat pressed the lever that was considered a correct response, a 
dispenser was triggered to release a sucrose pellet into the central pellet receptacle.  
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 Set-shifting task 
Set-shifting was conducted as described in the previous chapter (see 2.3.4). One 
day after performing the visual-cue discrimination task, rats received an intra-mPFC 
bilateral infusion of one of the drug treatments (0.025 μg or 0.05 μg SCH 23390; 0.125 
μg or 0.25 μg MK-801; 0.025 μg SCH 23390 + 0.125 μg MK-801; or 0.9% saline). Seven 
minutes later, rats were subjected to 20 visual-cue discrimination trials to determine the 
effect of the various drug treatments on memory retrieval of the initial strategy (i.e., 
follow the cue light). On the 21st trial, the paradigm was switched to a response 
discrimination, in which the rats had to set-shift and now respond on the lever opposite to 
their side bias during every trial regardless of the location of the stimulus light. Again, 
each trial began with the random illumination of a stimulus light, followed 3 s later by the 
extension of both levers. Correct lever presses within the 10 s response window resulted 
in delivery of a sucrose pellet. The response discrimination session ended when either the 
rat made 10 consecutive correct responses or if the maximum number of 120 trials was 
performed. Total number of trials to criterion and errors committed to achieve criterion 
were recorded. 
 In accordance with previous studies (Floresco et al., 2008; Desai et al., 2017), the 
errors committed during the response discrimination task (i.e., set-shifting) were sub-
divided into three categories as perseverative, regressive or never-reinforced errors. An 
error was considered “perseverative” or “regressive” if during the response 
discrimination task, the rat pressed the lever associated with the illuminated stimulus 
light when the opposite lever was correct. In a block of 16 randomized trials, 8 trials 
required the rat to press the lever opposite to the stimulus light (i.e., the rat was faced 
with a chance to make a perseverative error). If the rat committed 6 or more such errors 
out of the 8 chances, these errors in that block were considered “perseverative” errors, 
whereas 5 or fewer such errors were instead considered “regressive” errors, as the rat was 
following the initial visual-cue strategy in less than 75% of trials (Floresco et al., 2008). 
A “never-reinforced error” occurred when the stimulus light was illuminated above the 
correct lever, yet the rat pressed the opposite lever; a choice that had never resulted in a 
pellet in either the visual-cue or response discrimination task. 
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3.3.6.1 Visual-cue learning paradigm 
  To determine if the intra-mPFC co-infusion of the lower doses of SCH 23390 + 
MK-801 affected learning of a given lever-pressing rule as opposed to actual set-shifting, 
we conducted an experimental on a separate group of naïve rats (Figure 3.7). Rats were 
acclimatized and trained to press the levers using the same protocol as described before 
(2.3.4). The next day, these rats received an intra-mPFC infusion of either 0.025 μg SCH 
23390 + 0.125 μg MK-801 on each side (n=7) or vehicle (saline; n=7), and 7 min later, 
were tested on their ability to learn the visual-cue discrimination task. These groups of 
rats were never subjected to the set-shifting experiment.  
 Histology 
 Upon completion of the response discrimination task, rats were given an overdose 
of sodium pentobarbital (Euthanol, 105 mg/kg, IP; MTC Pharmaceuticals, Cambridge, 
ON, Canada), and then perfused trans-cardially with 0.9% saline followed by a solution 
containing 4% formaldehyde in phosphate buffer (pH 7.4). Brains were extracted, post-
fixed in 4% formaldehyde solution overnight, and then cryoprotected by storing in 30% 
sucrose at 4 °C for 3 days. Using a microtome, 40 μm coronal sections of mPFC were cut 
and collected in phosphate buffer (pH 7.4). Sections were mounted on glass slides and 
Nissl stained to verify cannulae placements (Figure 3.9). Every rat infused showed 
cannula placement within the prelimbic area bilaterally, and consequently, all are 
included in the analysis. 
 Statistical analysis 
 The effects of intra-mPFC drug infusion on visual-cue retrieval, trials and errors 
to criterion, and number of omissions were analyzed by separate one-way analyses of 
variance (ANOVA). Two-way mixed ANOVAs were used to determine the effect of 
treatments on the type of errors committed, as well as the latency to respond on the 
levers. In a separate group of rats, a two-tailed student’s t-test was used to compare the 
performance of the visual-cue learning paradigm following infusion of the combined 
drug treatment (0.025 μg SCH 23390 + 0.125 μg MK-801) versus the saline control. All 
statistical analyses were conducted with α = 0.05 using GraphPad Prism 7.0 software. 
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When needed, Tukey’s post hoc test was employed to compare the performance measures 
across the various drug treatment groups. All data are presented as mean ± standard error 
of mean (SEM). 
 
 
 
 
  
Figure 3.1 Timeline of Experiment 1 and 2. 
A) In Experiment 1, following handling and acclimatization to the chamber, the rats were 
subjected to training. Once the rats achieved the criterion for the training session, their side 
bias was determined on the final day of training. On the next day, rats were subjected to 
visual-cue discrimination, and the following day was the response discrimination (set-
shifting) test. On the response discrimination day, the rats received bilateral intra-mPFC 
infusion of drugs or vehicle, and 7 min later, they were subjected to 20 visual-cue 
discrimination trials to determine the effect of drug treatments on retrieval of the memory 
and motor function. On the 21st trial, the paradigm was switched from a visual-cue 
discrimination to a response discrimination that lasted until either the rat made 10 
consecutive correct responses or to the maximum number of 120 trials. B) Experiment 2 
was performed on a separate group of naïve rats that received the bilateral intra-mPFC 
infusion of drugs or vehicle prior to the initial exposure to the visual-cue discrimination 
task. Rats employed in Experiment 2 were never subjected to set-shifting trials. 
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3.4 Results 
 Effect of SCH 23390, MK-801 or combined antagonist infusion on 
visual-cue retrieval  
 On the day set-shifting task was performed, the initial 20 trials after the intra-
mPFC infusion required each rat to respond on the lever associated with the stimulus 
light, thereby allowing for the investigation of the effect of the various drug infusion on 
memory retrieval of the initial visual-cue discrimination strategy. As predicted based on 
previous studies (Ragozzino et al., 2002a; c; Stefani et al., 2003; Stefani and 
Moghaddam, 2005; Gauthier et al., 2014), none of the drug infusion affected memory 
retrieval (one-way ANOVA, P>0.05; Figure 3.2), as all rats (n=7 per group) showed a 
high level of performance. 
  
Figure 3.2 Effect of intra-mPFC infusion of SCH 23390 and MK-801 alone or in 
combination on visual-cue retrieval. 
On the set-shift day (during the 20 trials prior to the response discrimination task), intra-
mPFC infusion of SCH 23390 and MK-801 alone or in combination did not affect retrieval 
of the memory from the previous day (visual-cue discrimination task), as the number of 
errors committed during the 20 visual-cue trials was comparable across groups (one-way 
ANOVA, P>0.05). n=7 per group. 
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 Effect of SCH 23390, MK-801 or combined antagonist infusion on 
set-shifting 
3.4.2.1 Number of trials to criterion  
 One-way ANOVA found that the various drug doses infused into the mPFC 
differentially affected the number of trials needed to complete the set-shifting task 
[F(5,36) = 11.8, P<0.0001; Figure 3.3]. Tukey’s post hoc testing further revealed that, 
compared to vehicle-treated controls (n=7), the groups of rats infused with the higher 
dose of either SCH 23390 (0.05 g/side; n=7) or MK-801 (0.25 g/side; n=7) showed a 
significant increase in the total number of trials to criterion (Figure 3.3). In contrast, the 
lower doses of SCH 23390 (0.025 g/side) or MK-801 (0.125 g/side) were ineffective 
at altering set-shifting performance.  
As predicted, Tukey’s post hoc testing confirmed that the groups of rats that 
received the co-infusion of the lower, “behaviourally sub-effective” doses of SCH 23390 
(0.025 g/side) and MK-801 (0.125 g/side) showed an increased number of trials to 
complete the set-shifting task compared to controls (P<0.0001) as well as the individual, 
lower dose groups (0.025 g/side SCH 23390 alone, P<0.01; 0.125 g/side MK-801 
alone, P<0.001). 
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Figure 3.3 Effect of intra-mPFC infusion of SCH 23390 and MK-801 alone or in 
combination on trials to criterion during set-shifting. 
Intra-mPFC infusion of the individual lower doses of SCH 23390 (0.025 g/side) or MK-
801 (0.125 g/side) did not affect number of trials to criterion (P>0.05) as compared to 
control group. In contrast, the higher dose of SCH 23390 (0.05 g/side) significantly 
increased the number of trials to criterion as compared to the control (***P<0.001), 
lower dose SCH 23390 ($$P<0.01) and lower dose MK-801 groups (###P<0.001). 
Similarly, infusion of the higher dose of MK-801 (0.25 g/side) significantly increased 
the trials to criterion as compared to the control (*P<0.05) and lower dose MK-801 
groups (#P<0.05). As predicted, the co-infusion of the lower doses of SCH 23390 and 
MK-801 significantly increased the trials to criterion as compared to the control 
(****P<0.0001), lower dose SCH 23390 ($$P<0.01) or lower dose MK-801 groups 
(###P<0.001). Finally, the number of trials to criterion following the individual higher 
dose infusion was comparable to the co-infusion group (P>0.05). One-way ANOVA 
followed by Tukey’s post hoc tests. n=7 per group.  
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3.4.2.2 Number of errors to criterion  
One-way ANOVA revealed effects of different drug treatments on number of 
errors committed during set-shifting task [F(5,36) = 14.82, P<0.0001; Figure 3.4]. Post 
hoc analysis revealed that, compared to control group (n=7), the groups infused with the 
higher dose of either SCH 23390 (0.05 g/side; n=7) or MK-801 (0.25 g/side; n=7) 
showed a significant increase in errors to criterion. 
Co-infusion of lower doses of SCH 23390 and MK-801 significantly increased 
number of errors committed as compared to the controls (P<0.001) or separate lower 
dose infusion of SCH 23390 (P<0.001) or MK-801 (P<0.0001). 
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Figure 3.4 Effect of intra-mPFC infusion of SCH 23390 and MK-801 alone or in 
combination on errors to criterion during set-shifting. 
The number of errors committed by either of the groups receiving the lower doses of SCH 
23390 (0.025 g/side) or MK-801 (0.125 g/side) were comparable to those committed 
by the control group (P>0.05). Following infusion of the higher dose of SCH 23390 (0.05 
g/side), rats committed significantly more errors as compared to the control 
(****P<0.0001), lower dose SCH 23390 ($$$P<0.001) and lower dose MK-801 groups 
(####P<0.0001). In agreement, intra-mPFC infusion of the higher dose of MK-801 (0.25 
g/side) significantly increased the number of errors committed versus the control 
(*P<0.05), lower dose SCH 23390 ($P<0.05) and lower dose MK-801 groups 
(##P<0.01). Co-infusion of the lower, individually-ineffective doses of SCH 23390 and 
MK-801 significantly increased the number of errors made compared to the control 
(***P<0.001), lower dose SCH 23390 ($$$P<0.001) and lower dose MK-801 groups 
(####P<0.0001). Lastly, the number of errors committed by either of the higher dose 
groups was comparable to those of the co-infusion group. One-way ANOVA followed by 
Tukey’s post hoc tests. n=7 per group. 
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3.4.2.3 Type of errors 
 Errors committed during the set-shifting task were divided in three subgroups 
(perseverative, regressive and never-reinforced errors) and the effect of the different drug 
infusion on these error types was analyzed using a two-way, mixed ANOVA with 
“treatment” as the between-subject factor and “error type” as the within-subject factor, as 
described previously (Darrah et al., 2008; Floresco et al., 2008; Snyder et al., 2015; Desai 
et al., 2017). In addition to reporting significant main effects for both treatment [F(5,30) 
= 15.94, P<0.0001] as well as error type [F(2,12) = 967.7, P<0.0001], the two-way, 
mixed ANOVA found an interaction between the factors [F(10,60) = 11.19, P<0.0001]. 
Ultimately, Tukey’s post hoc testing revealed a significant increase in perseverative 
errors committed by the co-infusion group (0.025 μg/side SCH 23390 + 0.125 μg/side 
MK-801) compared to the saline (P<0.0001), lower dose SCH 23390 (P<0.0001) or 
lower dose MK-801 groups (P<0.0001) (Figure 3.5). The number of regressive and 
never-reinforced errors did not differ between groups (P>0.05).  
Figure 3.5 Intra-mPFC infusion of SCH 23390 and MK-801 alone or in combination 
differentially affected the error profile during set-shifting. 
Both groups that received the individual higher doses of the antagonists (SCH 23390 0.05 
g/side; MK-801 0.25 g/side) showed a significant increase in the number of perseverative 
errors made compared to the control (****P<0.0001), lower dose SCH 23390 (0.025 g) 
($$$$P<0.0001) and lower dose MK-801 groups (0.125 g) (####P<0.0001). Similar results were 
observed for the group co-infused with the lower doses of the SCH 23390 + MK-801. The 
number of regressive and never-reinforced errors was not changed across groups (P>0.05). 
Mixed two-way ANOVA followed by Tukey’s post hoc tests. n=7 per group. 
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 Response latencies and omissions 
For rats in each of the drug infusion groups, the latency to respond on the 
extended levers was compared for last five trials of the following trial types: i) correct 
response on non-perseverative trials, ii) correct response on trials where a perseverative 
error was possible, and iii) perseverative error trials. Response latencies did not differ 
between groups or during the various trial types (two-way mixed ANOVA, P>0.05; 
Figure 3.6). These data suggest that motor function was not affected by the various drug 
infusion. 
Figure 3.6 Effect of intra-mPFC infusion of antagonists alone or in combination on latencies 
to response during different types of trial. 
Latencies to respond on the extended lever during the different types of trials were not affected by 
the treatment groups (two-way ANOVA, P>0.05). Different types of trial included: i) 
Correct/non-perseverative: A trial where the rat chose the correct lever when the illuminated 
visual-cue light was associated with the correct lever; ii) Correct perseverative chance: A correct 
response on a trial where a perseverative error was possible; and iii) Perseverative error: An 
incorrect choice where the rat responded on the lever with the visual-cue light illuminated above 
it when the opposite lever was correct. n=7 per group. 
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 Omissions 
The number of omissions made during the set-shifting task was comparable 
across all the groups (one-way ANOVA, P>0.05; Figure 3.7). 
 
 
  
Figure 3.7 Effect of intra-mPFC infusion of antagonists alone or in combination on the 
number of omissions committed during set-shifting. 
None of the treatments significantly changed the number of omissions committed during  
set-shifting as compared to the vehicle group (One-way ANOVA, P>0.05, n=7 per group). 
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 Effect of co-infusion of receptor antagonists on visual-cue learning 
In Experiment 2, the separate group of naïve rats (n=7) that received the bilateral 
intra-mPFC saline infusion prior to the visual-cue learning paradigm were able to 
complete the task in ~30 trials (Figure 3.8). Compared to these controls, the rats (n=7) 
that received the co-infusion of the lower doses of SCH 23390 + MK-801 (0.025 μg/side 
SCH 23390 + 0.125 μg/side MK-801) did not differ in the number of trials to criterion 
[two-tailed student’s t-test, t(12)=0.775, P>0.05]. Thus, the intra-mPFC co-infusion of 
these “behaviourally sub-effective” doses of antagonists did not affect the rats’ ability to 
learn a new set of rules. 
 
 
 
 
 
 
 
  
  
 
Figure 3.8 Intra-mPFC co-infusion of the lower, individually-ineffective doses of 
antagonists did not impair learning. 
In Experiment 2, in a separate group of rats (n=7), prior to performance of the initial 
visual-cue discrimination task, the lower doses of SCH 23390 (0.025 g/side) and MK-
801 (0.125 g/side) were co-infused into the mPFC. This combined treatment did not 
affect visual-cue learning as compared to the control group (n=7) that received saline 
infusion prior to performing the task (student’s t-test, P>0.05). 
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A B 
Figure 3.9 Representative histology and reconstruction of infusion cannulae location in 
mPFC. 
A) A photomicrograph showing that the bilateral infusion cannulae targeted the prelimbic (PL) 
region of the mPFC in a representative animal. B) Schematic images of successive coronal 
sections (adapted from Paxinos and Watson 2007) showing the location of the ends of the 
infusion cannulae in all animals used in the present study (n=56).  
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3.5 Discussion  
 In the present study, we used an operant conditioning-based task in rats to 
investigate if the combined, intra-mPFC infusion of low, individually-ineffective doses of 
dopamine D1 and NMDA receptor antagonists would be sufficient to impair set-shifting. 
Ultimately, in agreement with our working hypothesis, we report for the first time that 
coincident blockade of dopamine D1 and NMDA receptors in the mPFC is impairs 
behavioural flexibility. Moreover, our collective findings support the suggestion that 
perseverance can manifest from a seemingly mild but coincidental disruption in both 
dopaminergic and glutamatergic neurotransmission within the mPFC.  
Over the past two decades, a variety of preclinical rodent models have been 
developed to investigate the brain regions and neurotransmitter systems underlying 
deficits in set-shifting, with many of these models being based on digging behaviour, 
maze navigation or conditioned lever-pressing in operant chambers (Birrell and Brown, 
2000; Stefani et al., 2003; Ghods-Sharifi et al., 2008; Enomoto et al., 2011; Tait et al., 
2014). Largely consistent among these set-shifting tasks, rodents must suppress their 
actions associated with a previously-learned response, rule or strategy, successfully 
sample novel strategies and eliminate those that are disadvantageous, and finally, adhere 
to the newly-effective strategy (Block et al., 2007; Floresco et al., 2008, 2009). 
Importantly, these overlapping stages of set-shifting appear to have a differential 
susceptibility to disturbed activity in certain brain regions, as evidenced with distinct 
error profiles. For example, local damage/inactivation of the mPFC results in an inability 
to disengage from the initial strategy (i.e., increased perseverative errors) (Ragozzino et 
al., 1999; Ghods-Sharifi et al., 2008; Enomoto et al., 2011), whereas as the number of 
never-reinforced or regressive errors were increased following inactivation of the nucleus 
accumbens (Floresco et al., 2006a) or dorsal striatum (Ragozzino et al., 2002c), 
respectively.  
 In addition to lesioning/inactivating the mPFC, it is well established that the 
number of perseverative errors also increases following local blockade of the 
dopaminergic (Crofts et al., 2001; Ragozzino, 2002a; Floresco et al., 2006b) or 
glutamatergic neurotransmitter systems (Stefani et al., 2003; Stefani and Moghaddam, 
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2005). In agreement with these previous studies, we found that intra-mPFC infusion of 
the higher doses of either the dopamine D1 receptor antagonist, SCH 23390, or the 
uncompetitive NMDA receptor antagonist, MK-801, caused impaired set-shifting via 
increased perseverance. In considering the effect of the separate disturbance of 
dopaminergic or glutamatergic neurotransmission within the mPFC, it is worth noting 
that the individual doses used to impair set-shifting in the present study (SCH 23390: 
0.05 g/side; MK-801: 0.25 g/side) were previously found to be ineffective at altering 
performance during various working memory tasks (Seamans et al., 1998; Romanides et 
al., 1999; Rios Valentim et al., 2009; Rodrigues et al., 2011; Auger and Floresco, 2017). 
Taken together, these findings highlight the seemingly heightened susceptibility of 
behavioural flexibility to altered neurotransmission within the mPFC.  
 To investigate our working hypothesis that intra-mPFC synergism between 
dopamine and glutamate abnormalities cause impaired set-shifting, a group of rats were 
infused intra-mPFC with a combination of the doses of SCH 23390 and MK-801 that 
were low enough to be ineffective at impairing set-shifting when infused separately. As 
predicted, the intra-mPFC co-infusion caused a significant increase in the number of 
trials and errors to criterion as well as perseverative errors committed. To our knowledge, 
these results provide the first evidence that behavioural flexibility is sensitive to a mild 
degree of co-disruption of dopamine D1 and NMDA receptors within the mPFC. In fact, 
set-shifting appears to be particularly sensitive to disruption in both dopaminergic and 
glutamatergic neurotransmission as the doses of antagonists used to cause perseverance 
failed to affect either the acquisition of the visual-cue strategy or memory retrieval. 
However, in contrast to these null effects, Baldwin et al, (2002) reported that daily co-
infusion of low, individually-ineffective doses of dopamine D1 and NMDA receptor 
antagonists into the mPFC impaired the acquisition of a lever-pressing behaviour over a 
multi-day instrumental learning task. It is reasonable to suggest that these disparate 
results on learning could be due to the actual doses used (e.g., SCH 23390: 0.025 μg/side 
in the present study vs. 0.05 μg/side in Baldwin et al, (2002) as well as differences in the 
task demands (e.g., unlike in the present study, the first exposure their rats had to lever-
pressing occurred following co-infusion of the antagonists). Irrespective of the 
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experimental differences between studies, the collective findings identify the importance 
of coincident activation of dopamine D1 and NMDA receptors in the mPFC.  
At present, it remains unknown, which cellular mechanisms underlie the impaired 
set-shifting observed following co-infusion of the dopamine D1 and NMDA receptor 
antagonists. That said, considerable research has investigated the interactions between D1 
and NMDA receptors. There is evidence of co-localization of dopamine D1 receptors and 
NMDA receptors in the same pyramidal neuron or interneuron in the PFC (Kruse et al., 
2009), and numerous in vitro studies have shown a synergism at the receptor level 
between the D1 and NMDA receptors. For example, NMDA receptors were shown to 
modulate D1 receptor-mediated functions, as blocking NMDA receptors leads to an 
attenuation of the ability of the D1 receptor to affect neuronal activity (Huang et al., 
1998; Zheng et al., 1999). Reciprocally, activation of D1 receptors is known to 
upregulate the activity of NMDA receptors (Gurden et al., 2000; Wang and O’Donnell, 
2001; Chen and Yang, 2002; Flores-Hernández et al., 2002; Chen et al., 2004; Hallett et 
al., 2006; Kruse et al., 2009; Sarantis et al., 2009; Varela et al., 2009; Li et al., 2010; Nai 
et al., 2010). Moreover, uncoupling of the D1-NMDA interaction was found to prevent 
the D1 receptor-induced upregulation of long-term potentiation (LTP) (Nai et al., 2010).  
 In addition to the aforementioned D1-NMDA interactions, it has been shown that 
D1 receptors can modulate NMDA currents through a PKA-dependent intracellular 
signaling pathway (Flores-Hernández et al., 2002; Cepeda and Levine, 2006). At the level 
of animal behaviour, Kelley and colleagues reported that the repeated infusion of a 
selective PKA inhibitor into either the mPFC (Baldwin et al., 2002) or nucleus 
accumbens (Smith-Roe and Kelley, 2000) of rats attenuated instrumental learning during 
a multi-day lever-pressing task; findings that were consistent to those following co-
infusion of individually-ineffective doses of dopamine D1 and NMDA receptor 
antagonists. Given that we found an impairment in set-shifting following similar co-
infusion of receptor antagonists into the mPFC, it will be important for future studies to 
determine if the selective inhibition of the PKA-pathway influences behavioural 
flexibility.  
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 The increased perseverance observed in the present study following the intra-
mPFC co-infusion of individually-ineffective doses of dopamine D1 and NMDA 
antagonists is consistent with the error profile of schizophrenia patients performing the 
WCST, as patients demonstrate difficulties in inhibiting a previously-learned strategy 
(Braff et al., 1991; Rosse et al., 1991; Abbruzzese et al., 1996; Perry and Braff, 1998; 
Gooding et al., 1999; Everett et al., 2001). Based on post-mortem studies of 
schizophrenia brains, a considerable loss of γ-amino butyric acid (GABA)-ergic, 
dopaminergic and glutamatergic activity in multiple cortical and subcortical areas has 
been proposed (Akil et al., 1999; Clinton and Meador-Woodruff, 2004; Lewis et al., 
2005; Lewis, 2014; Hu et al., 2015; Poels et al., 2015; Weinstein et al., 2017). For 
example, within the dlPFC of post-mortem schizophrenia brains, there is a 30% loss of 
dopaminergic fibers, as well as a severe loss of dendritic spines (Glantz and Lewis, 
2000), which suggests a corresponding loss of glutamatergic synapses. On the contrary, a 
recent study using positron emission tomography (PET) described a significant but small 
decrease in dopamine levels in the dlPFC in schizophrenia patients compared to controls, 
and proposed that the loss of dopaminergic activity could be minimal (Slifstein et al., 
2015). Ultimately, the results of the present study along with those of Baldwin et al, 
(2002) offer an important consideration for the future modeling of schizophrenia 
pathophysiology, as minimal but simultaneous blockade of dopamine D1 and NMDA 
receptors in the mPFC were found to be sufficient to significantly impair cognitive 
function. 
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 Molecular mechanisms associated with D1-NMDA receptor 
interaction mediated set-shifting in rats 
4.1 Abstract 
Prefrontal cortical interactions between dopamine and glutamate receptors are 
known to control cognitive functions. In our previous study, synergistic interaction 
between dopamine D1 and glutamate N-Methyl-D-aspartate (NMDA) receptor 
antagonists in the medial prefrontal cortex (mPFC) caused impaired set-shifting in rats. 
To find out molecular mechanisms underlying D1-NMDA receptor interaction in mPFC, 
we investigated i) involvement of protein kinase A (PKA) pathway in D1-NMDA 
receptor interaction mediated set-shifting behaviour ii) role of cortical extracellular 
regulated kinase (ERK) transduction signaling in set-shifting and iii) role of D1-NMDA 
receptor protein-protein interaction in set-shifting behaviour. We observed that, elevating 
mPFC levels of PKA by rolipram ameliorated set-shifting deficits caused by intra-mPFC 
co-infusion of behaviourally sub-effective doses of D1-NMDA receptor antagonists. 
Inhibiting ERK phosphorylation by intra-mPFC infusion of mitogen-activated protein 
kinase (MAPK) inhibitor PD98059 resulted in deficits in set-shifting behaviour. 
PD98059-induced set-shifting impairments were not ameliorated by rolipram. Blocking 
protein-protein interaction between D1 and NMDA by Fyn kinase inhibitor- PP2 did not 
have any effect on set-shifting behaviour. In conclusion, in the mPFC, a strong 
synergistic interaction between D1 and NMDA receptors exist, which regulates set-
shifting behaviour through PKA pathway. Further, for normal set-shifting, activation of 
ERK cascade is essential in the mPFC; and ERK signaling is downstream to PKA 
regulating set-shifting. Lastly, protein-protein interaction between D1-NMDA receptors 
through Fyn kinase does not have any role in set-shifting behaviour. 
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4.2 Introduction 
Executive functions are higher-order cognitive processes comprising behavioural 
flexibility (set-shifting and reversal learning), working memory and selective attention; 
and they are necessary for normal daily life activities including planning, problem-
solving, learning from the outcomes, changing responses and carrying out goal-directed 
behaviours (Hughes and Graham, 2002). A number of psychiatric disorders including 
schizophrenia, Alzheimer’s disease, autism and attention deficit hyperactivity disorder 
(ADHD) show impaired executive functions (Bornstein et al., 1990; Braff et al., 1991; 
Ozonoff, 1995; Collette et al., 1999; Perry and Hodges, 1999; Duke and Kaszniak, 2000; 
Elliott, 2003; Hill, 2004; Orellana and Slachevsky, 2013; Reddy et al., 2016). Across 
species studied, the prefrontal cortex (PFC) plays an important role in mediating 
executive function (Ragozzino et al., 1999; Monchi et al., 2001; Floresco et al., 2008; 
Moore et al., 2009; Tsuchida and Fellows, 2013; Déziel et al., 2015; Dalton et al., 2016).  
Infusion of dopamine D1, glutamate N-Methyl-D-aspartate (NMDA) or gamma-
Aminobutyric acid (GABA)-A receptor antagonists separately into the medial PFC 
(mPFC) cause impairment in working memory, set-shifting as well as attention in rodents 
(Seamans et al., 1998; Granon et al., 2000; Smith-Roe and Kelley, 2000; Ragozzino, 
2002; Stefani et al., 2003; Moghaddam and Jackson, 2003; Stefani and Moghaddam, 
2005; Paine and Carlezon, 2009; Enomoto et al., 2011; Su et al., 2014; Gauthier et al., 
2014; Paine et al., 2015; Auger and Floresco, 2017). We have recently reported impaired 
set-shifting in normal adult rats following systemic or intra-mPFC administration of D1 
receptor antagonist, SCH 23390, and a non-competitive NMDA receptor antagonist, MK-
801, in combination at doses that are ineffective when administered separately (Desai et 
al., 2017; see results, 3.4.2). This suggest a synergistic role for D1 and NMDA receptors 
in the mPFC in regulating set-shifting. Extensive literature has reported functional 
interactions between D1 and NMDA receptors playing critical role in reward, attention, 
locomotor activity, positive reinforcement, latent learning and working memory 
(Pulvirenti et al., 1991; Smith-Roe and Kelley, 2000; Kreipike and Walker, 2004; Missale 
et al., 2006; Castner and Williams, 2007; Mouri et al., 2007; Agnoli and Carli, 2011; 
Bishop et al., 2011; Wang et al., 2012a, 2012b). It is possible that D1 and NMDA 
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receptors from separate neurons of the mPFC to mediate such interaction via synaptic 
connections. Nevertheless, D1 receptors and NMDA receptors have been found to be 
present in same glutamatergic and GABAergic neurons of the mPFC and possibly 
localized in close proximity to each other (Kruse et al., 2009), and therefore, an 
intraneuronal D1-NMDA interaction cannot be overlooked. 
Synergistic interactions between D1 and NMDA receptors in the PFC and the 
nucleus accumbens in regulating cognitive processes such as working memory and 
instrumental learning have been investigated previously (Smith-Roe and Kelley, 2000; 
Baldwin et al., 2002b; Mouri et al., 2007; Rios Valentim et al., 2009). Baldwin et al. 
(2002b) reported that combined infusion of sub-effective doses of NMDA and D1 
receptor antagonists into the mPFC impaired instrumental learning in rats. In the same 
study, authors found that inhibiting protein kinase A (PKA) in the mPFC replicated effect 
of combined blocker treatment suggesting that cyclic AMP (cAMP)-dependent PKA 
cascade is involved in D1-NMDA interaction associated with the instrumental learning. 
Furthermore, in mice infusion of a D1 receptor agonist into the PFC attenuated the latent 
learning impairment caused by phencyclidine (PCP; a NMDA receptor antagonist), as 
well as decreased levels of learning associated phosphorylation of NR1 subunit of 
NMDA receptors in the mPFC suggesting a functional link between dopaminergic D1 
and glutamatergic NMDA receptor signaling through PKA (Mouri et al., 2007). In 
addition, NMDA-mediated cytosolic Ca++ elevation was enhanced by a D1 receptor 
agonist and this effect was blocked by PKA inhibitor (Kruse et al., 2009) (Figure 4.1). 
Moreover, in hippocampal-PFC synapses, NMDA-induced long-term potentiation (LTP) 
and excitability of pyramidal neurons were increased by D1 agonist or PKA activator 
while D1 antagonist or PKA blocker attenuated this effect (Gurden et al., 2000; Wang 
and O’Donnell, 2001). Although from aforementioned studies, it seems that PKA cascade 
plays a facilitatory role in D1-NMDA interaction and regulates cognitive behaviours and 
LTP, deleterious effect of PKA activation on working memory has also been reported 
(Taylor et al., 1999). 
 In addition to PKA, signaling mediated by the extracellular signal-regulated 
kinases (ERKs) also appears to play an important role in the synergistic interaction 
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between D1 and NMDA receptors. Co-infusion of small concentrations of D1 agonist and 
NMDA receptor agonists increased the levels of phosphorylation of NMDA and AMPA 
receptor subunits as well as ERK1/2, levels and this effect was blocked by inhibitors of 
ERK phosphorylation (Sarantis et al., 2009) suggesting that ERKs are downstream 
molecules involved in D1-NMDA interaction, and in turn ERK may facilitate excitatory 
neurotransmission by phosphorylating NMDA and AMPA receptor subunits (Figure 4.1). 
A separate mechanism underlying D1-NMDA receptor interaction has been proposed by 
Nai et al. (2010) who reported NMDA-D1 direct protein-protein interaction, which 
facilitated LTP and working memory in rats.  
Evidence indicate that interactions between D1 and NMDA receptors also occur 
through Fyn kinase pathway allowing functional cross-talk and potentiation of both types 
of receptors independent of PKA mechanism (Lee et al., 2002; Scott et al., 2002, 2006; 
Fiorentini et al., 2003; Cepeda and Levine, 2006; Li et al., 2010; Nai et al., 2010) (Figure 
4.1). Fyn kinase, a Src kinase family member (non-receptor tyrosine kinases), is activated 
following D1 receptors stimulation via ,  subunits of Gs protein and in turn 
phosphorylates NR2B subunit of NMDA receptors at Tyr1472, rendering NMDA 
receptors to be more effective in Ca++ conductance (Nakazawa et al., 2001). Moreover, a 
recent study identified strong evidence for reduced Src-family kinase activity in the PFC 
of post-mortem brains of patients with schizophrenia, a condition characterized by 
impaired executive function, and it has been proposed that Src-family kinases in the PFC 
might play a central role in cognitive deficits of schizophrenia (Hahn, 2011; Banerjee et 
al., 2015).  
Based on the above evidences, it appears that there is at least three main signaling 
pathways potentially mediate intraneuronal interaction between D1 and NMDA receptors 
in the mPFC. These are, i) PKA signaling; ii) ERK phosphorylation cascade and iii) Fyn 
kinase-mediated augmentation of NMDA function (Figure 4.1). In current study, we 
sought to investigate the role of PKA, ERK and Fyn kinase in regulating set-shifting. 
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Figure 4.1 Prefrontal cortical D1-NMDA receptor interactions and molecular signalling 
cascades associated with them. 
Stimulation of D1 receptors trigger adenylyl cyclase (AC)/cAMP/PKA cascade (Wang et al., 
2002). Although DARPP-32 is present in PFC, it may not be playing a crucial role in D1 
stimulation-activated protein kinase A (PKA) signalling cascade in the PFC (Sarantis et al., 
2009). NMDA receptor stimulation results in activation of signalling mechanism which 
ultimately increase phosphorylation of extracellular regulated kinase 1/2 (ERK1/2) through 
mitogen-activated protein kinase (MAPK) pathway (Chandler et al., 2001). D1-induced 
increase in PKA levels were found to potentiate NMDA mediated excitability as well as Ca++ 
influx of cortical pyramidal neurons (Wang and O’Donnell, 2001; Gonzalez-Islas and Hablitz, 
2003; Tseng and O’Donnell, 2004; Kruse et al., 2009). Further, coincidental activation of  D1 
and NMDA receptors or stimulation of  D1 receptors found to cause increased 
phosphorylation of  NMDA receptor subunits through ERK1/2 pathway (Nagai et al., 2007; 
Sarantis et al., 2009). Along with PKA and ERK pathways, D1-NMDA receptors interact with 
each other by direct protein-protein interaction through Fyn kinase-dependent mechanism; and 
a Fyn kinase inhibitor can disrupt this interaction (Gao and Wolf, 2008; Hu et al., 2010; Nai et 
al., 2010). 
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4.3 Materials and methods 
 Animals 
 Adult male Sprague-Dawley rats were used in this study (Charles River, Quebec, 
Canada). All rats were kept in facility with temperature- and humidity-controlled rooms 
(24±2 °C, relative humidity 55±10%). A12 h light/dark cycle (lights on at 7:00 am) was 
maintained. In preparation for behavioural training, rats were food restricted up to 85-
87% of their free feeding body weight, and they were handled for approximately five 
minutes per day to get familiarized to the investigator. During the food restriction, rats 
were given five sucrose pellets for the last five days prior to the start of training (45 mg; 
BioServ, Frenchtown, NJ) to make them to be familiar with the pellets that are used as a 
positive reinforcement in the behavioural tasks. All measures were taken to minimize the 
pain and suffering to animals at all time. Animals showing set-shifting deficit following 
drug treatments were reused one more time in this study. From our data, in naïve 
untreated animals, a 5-day washout period following the first run of set-shifting did not 
alter their performance on second run as the number of trials and errors to criterion as 
well as different types of errors committed during the first and second set-shifting were 
comparable (see results, 4.4.1). Our data is in accordance with Wallace et al. (2014). 
After washout period (5 days), animals to be reused were taken through exact same steps 
as their first exposure of set-shifting (n=14). All procedures were approved by the 
Institutional Animal Care Committee and are following the Canadian and National 
Institute of Health Guides for the Care and Use of Laboratory Animals (NIH Publication 
#80-23). 
 Drugs 
 The glutamate NMDA receptor uncompetitive antagonist (+) MK-801 (5S,10R)-
(+)-5-methyl-10,11-dihydro-5H-dibenzocyclohepten-5,10-imine hydrogen maleate; 
dizocilpine hydrogen maleate) and selective dopamine D1 receptor antagonist (R)-(+) 
SCH 23390 hydrochloride (R(+) 7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-
tetrahydro-1H-3-benzazepine hydrochloride) were dissolved in sterile saline to get 
desired concentrations. Fyn kinase inhibitor, PP2 (4-amino-3-(4-chlorophenyl)-1-(t-
butyl)-1H-pyrazolo[3,4-d]pyrimidine; a selective inhibitor of Src family kinases with 
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very high affinity to Fyn kinase), mitogen-activated protein kinase (MAPK) inhibitor, 
PD98059 (2ʹ-Amino-3ʹ-methoxyflavone; a selective inhibitor of MAP kinase kinase – 
MEK), and a selective inhibitor of phosphodiesterase 4 (PDE4), rolipram (4-[3-
(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) were dissolved in 3 % 
dimethylsulfoxide (DMSO) to achieve desired concentrations. All the drugs were 
procured from Sigma-Aldrich (St. Louis, MO, USA). Fresh solutions were prepared on 
the day of injection, and stored in a refrigerator between injections in successive animals. 
All infusions were made with solutions at room temperature. Control group of animals 
received infusion of sterile saline or 3% DMSO in saline as appropriate. 
 Surgery 
 Rats were anesthetized with isoflurane (Forene®, Baxter Corporation, 
Mississauga, ON Canada), mounted in a stereotaxic frame, and injected with Metacam 
(Boehringer Ingelheim, Burlington, ON, Canada) and an antibiotic (Baytril®, Bayer Inc., 
Toronto, ON, Canada). For intra-mPFC drug infusion, bilateral guide cannulae (27 G, 2 
mm length; RWD Life Science Inc., San Diego, CA, USA) were implanted using 
stereotaxic coordinates to target the prelimbic cortex (relative to bregma: AP= + 3.24, 
ML= ± 0.8, DV= −1.5 mm from skull surface; Paxinos and Watson, 2007). These guide 
cannulae were secured to the skull with four jeweller’s screws and dental cement. 
Stainless steel dummy cannulae were inserted into the guide cannulae to prevent clogging 
in between the micro-infusion. During surgical recovery period, rats were handled daily 
at various procedures, including general care, weighing and cleaning of dummy cannulae.  
 Micro-infusion procedure 
 Intra-mPFC injections were performed in awake animals using infusion cannulae 
that extended 2 mm beyond the length of the guide cannulae. On the experimental day, 
rats received one of the following bilateral infusion into the mPFC: i) co-infusion of 
rolipram (2.5 μg) with SCH 23390 (0.025 μg) + MK-801 (0.125 μg); ii) rolipram alone 
(2.5 μg); iii) PD98059 alone (2.67 μg); iv) co-infusion of rolipram (2.5 μg) + PD98059 
(2.67 μg); v) PP2 alone (3.0 ng); vi) vehicle (3% DMSO or saline). For co-infusion, 
drugs solutions were diluted to obtain the appropriate concentrations of individual drugs 
in 0.5 μL volume per site. Doses of PD98059 and PP2 we chose were commonly used in 
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in vivo studies where they showed impaired cognitive functions and expected changes in 
the levels phosphoproteins (Grosshans and Browning, 2001; Bevilaqua et al., 2003; 
Gerdjikov et al., 2004; Nagai et al., 2007; Liu et al., 2014). In addition, in pilot studies, 
we have verified efficacy and possible motor effects of rolipram, PD98059 and PP2 that 
could interfere non-specifically with behavioural testing (2-3 doses per drug; 2-3 rats per 
group). Both sides were infused simultaneously using a microinfusion pump and 
Hamilton syringes connected to the infusion cannula via Teflon tubing. Infusions were 
made over 5 min (0.1 μL/min), and the infusion cannulae were left in place for an 
additional 2 min to allow diffusion of the drug into the surrounding brain tissue and to 
minimize solutions escaping via the cannula tract. 
 Behavioural apparatus 
 Behavioural training and testing was performed in an operant conditioning 
apparatus, which included a modular acrylic test chamber (30.5 x 24 x 21 cm). Front wall 
of the test chamber had two stimulus lights, each located above a retractable lever that 
was positioned on either side of a central pellet receptacle. A house light was located on 
the back wall of the chamber. The chamber was operated through a customized computer 
software program (MED-PC IV, Med-Associates). Trial by trial data was recorded during 
all the procedures performed in the box. 
 Set-shifting task 
 Behavioural flexibility was assessed using a set-shifting task adapted from 
Floresco et al. (2008). This task has been described in detail in our recent study (Desai et 
al., 2017 see 2.3.4). Following series of steps were involved in testing set-shifting: 
acclimatization and training, side-bias determination, initial set formation (visual-cue 
discrimination) and set-shifting (response discrimination). 
 Histology 
 Following set-shifting, rats were given an overdose of sodium pentobarbital 
(Euthanol, 105 mg/kg, i.p.; MTC Pharmaceuticals, Cambridge, ON, Canada), and 
intracardially perfused with 0.9% saline followed by a solution containing freshly 
prepared 4% formaldehyde in phosphate buffer (pH 7.4). Brains were extracted, post-
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fixed in the same formaldehyde solution overnight, and then cryoprotected by storing in 
30% sucrose in phosphate buffer at 4 °C for 3-4 days. Using a microtome, 40 μm coronal 
sections through the mPFC were cut and collected in phosphate buffer. Sections were 
mounted on glass slides and Nissl stained to verify cannulae placements (Figure 4.12). 
 Statistical analysis 
 Effect of co-infusion of rolipram with dual combination on visual-cue retrieval, 
trials and errors to criterion, and number of omissions committed during set-shifting was 
analyzed by one-way analysis of variance (ANOVA). A two-way mixed ANOVA was 
used to determine the effect of treatments on the type of errors committed, as well as the 
latency to respond on the levers. Following ANOVAs, if needed, Tukey’s or Bonferroni’s 
post hoc test was employed to compare the performance measures across the groups. A 
two-tailed student’s test was used to assess effect of re-exposure of set-shifting, effect of 
PD98059 and PP2 on visual-cue retrieval, trials and errors to criterion during set-shifting 
and number of omissions committed during set-shifting in comparison with respective 
control groups. Further, student’s t-test was also used to assess effect of PD98059 on 
visual-cue learning. All statistical analyses were conducted with  = 0.05 using 
GraphPad Prism 7.0 software. All data are presented as mean  standard error of mean 
(SEM). 
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4.4 Results  
 Effect of re-testing rats on behavioural pattern during set-shifting. 
4.4.1.1 Trials and errors to criterion 
 Following first set-shifting rats were given washout period of 5 days. Re-exposure 
to training and set-shifting did not affect number of trials [t(10)=0.4593, P>0.05] (n=6) 
and errors to criterion [t(10)=0.3339, P>0.05] (n=6; Figure 4.2 A,B; student’s t-test).  
  
Figure 4.2 Effect of re-exposure to set-shifting on performance. 
A) Number of trials to criterion by normal untreated naïve rats during first and the 
second exposure to set-shifting were comparable (P>0.05). Student’s t-test; n=6 
per group. B) Number of errors committed by rats performing set-shifting for 
second time were comparable to the number of errors committed during their 
performance on the first time (P>0.05). Student’s t-test; n=6 per group.  
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4.4.1.2 Type of errors 
During re-exposure to set-shifting, number of perseverative, regressive and never-
reinforced errors were comparable between two runs of set-shifting 
[F(1,5) = 0.1018, P=0.7626] (Figure 4.3; two-way ANOVA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.3 Effect of re-exposure to set-shifting on type of errors. 
Number of perseverative, regressive and never-reinforced errors committed during both set-shifting 
sessions were comparable (P=0.7626) two-way ANOVA; n=6 per group.  
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 Reduced Fyn kinase activity in the mPFC does not affect set-
shifting  
4.4.2.1 Trials and errors to criterion 
Intra-mPFC infusion of PP2 (3 ng/side) in naïve rats did not affect set-shifting. 
Student’s t-test did not show any significant change in the number of trials to criterion 
[t(12)=0.2269, P>0.05; n=7 each] (Figure 4.4 A) or the number of errors to criterion 
[t(12)=0.1572, P>0.05; n=7 each] in rats infused with PP2 in comparison to vehicle-
infused animals (Figure 4.4 B). 
 
  
Figure 4.4 Effect of intra-mPFC infusion of PP2 on number of trials and errors to 
criterion during set-shifting. 
A) As compared to vehicle group, intra-mPFC infusion of Fyn kinase inhibitor PP2 (3 ng/side) 
did not affect trials to criterion during set-shifting (P>0.05). Student’s t-test; n=7 per group. B) 
Intra-mPFC PP2 treatment did not affect errors to criterion as compared to vehicle group 
(P>0.05). Student’s t-test; n=7 per group. 
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4.4.2.2 Type of errors 
A two-way, mixed ANOVA with “treatment” as the between-subject factor and 
“error type” as the within-subject factor, was used in the analysis of error profile as 
described in the literature (Darrah et al., 2008; Floresco et al., 2008; Jones et al., 2014; 
Snyder et al., 2015; Desai et al., 2017). Results showed that in naïve rats PP2 (3 ng/side) 
treatment did not show any significant difference compared to control group in 
committing perseverative errors while performing set-shifting task 
[F(1,6) = 0.017, P=0.9003]. Furthermore, regressive and never-reinforced errors were 
comparable between PP2 and vehicle groups (P>0.05) (Figure 4.5).  
 
  
Figure 4.5 Effect of intra-mPFC infusion of PP2 on type of errors during set-shifting.  
Number of perseverative, regressive as well as never-reinforced errors was comparable 
between PP2 and vehicle groups (P>0.05). Two-way ANOVA; n=7 per group. 
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 Increasing PKA activity in the mPFC rescues co-infusion of D1 
and NMDA blockers-induced impairment in set-shifting 
4.4.3.1 Trials and errors to criterion 
From our previous study, (see results 3.4.2), co-infusion of behaviourally sub-
effective doses of D1 receptor and NMDA receptor blockers (0.025 μg/side SCH 23390 + 
0.125 μg/side MK-801; referred to as dual combination treatment) bilaterally into the 
mPFC caused impairment in set-shifting in rats by increasing trials to criterion 
[F(3,24) = 13.75, P<0.0001] as well as errors to criterion [F(3,24) = 10.7, P<0.0001] 
(one-way ANOVA followed by Tukey’s post hoc test; n=7), whereas separate infusion of 
the same low doses of SCH 23390 or MK-801 into the mPFC bilaterally did not affect 
set-shifting (P>0.05).  
In order to identify the potential signaling cascade downstream to D1 receptors in 
mediating set-shifting, we augmented the activity of the most prominent D1 receptor 
signaling pathway, the PKA signaling by co-infusing animals with dual combination 
treatment and rolipram (2.5 μg/side). The number of trials required to achieve the 
criterion [F(3, 24) = 13.75, P<0.0001] and the number of errors committed before 
reaching the criterion [F(3, 24) = 10.7, P<0.0001] were significantly decreased compared 
to those following the dual combination treatment (Figure 4.6 A,B; one-way ANOVA 
followed by Tukey’s post hoc test). As hypothesized, co-infusion of rolipram with the 
dual combination treatment significantly ameliorated the deficits. The group that received 
co-infusion of rolipram and the dual combination treatment showed comparable number 
of trials as well as number of errors to criterion with vehicle- or rolipram alone-treated 
groups (P>0.05). Infusion of rolipram alone, however, did not affect set-shifting and the 
observed trials and errors to criterion were similar to that of vehicle treatment (P>0.05), 
indicating a lack of pro-cognitive effect of rolipram per se in naïve rats at this dose when 
infused into the mPFC. 
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Figure 4.6 Effect of rolipram on dual combination-induced set-shifting impairments. 
A) Intra-mPFC infusion of dual combination (0.025 μg/side SCH 23390 + 0.125 μg/side MK-801) 
significantly increased trials to criterion during set-shifting as compared to vehicle (***P=0.0002) 
and rolipram alone groups (####P<0.0001). This effect was attenuated significantly by co-infusion of 
rolipram (2.5 μg/side) ($$P<0.01). Number of trials taken by co-infused group and vehicle group 
were comparable (P>0.05). One-way ANOVA followed by Tukey’s post hoc test; n=7 per group, 
for rolipram alone group. B) Dual combination treatment (0.025 μg/side SCH 23390 + 0.125 
μg/side MK-801) significantly increased number of errors committed during set-shifting as 
compared to vehicle (**P<0.01) and rolipram per se (###P<0.001) groups. Combining rolipram 
with dual combination significantly ameliorated this effect ($P<0.05). Further, co-infused group and 
vehicle group committed comparable number of errors during set-shifting (P>0.05). One-way 
ANOVA followed by Tukey’s post hoc test; n=7 per group. 
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4.4.3.2 Type of errors 
A significant main effects of treatment [F(3,18) = 7.862, P<0.001] as well as 
error type [F(2,12) = 1376, P<0.0001], and a significant interaction between the factors 
[F(6,36) = 10.42, P<0.0001] were seen. Post hoc testing revealed a significant increase in 
perseverative errors committed following the dual combination group as compared to the 
vehicle and rolipram alone (P<0.00001) (Figure 4.7). Co-infusion of rolipram (2.5 
μg/side) with the dual combination treatment significantly decreased perseverative errors 
compared to dual combination group (P<0.00001). The number of regressive and never-
reinforced errors did not change across all groups tested (P>0.05). 
  
Figure 4.7 Effect of rolipram on dual combination-induced increased perseverance. 
Intra-mPFC treatment of dual combination (0.025 μg/side SCH 23390 + 0.125 μg/side MK-801) 
significantly increased number of perseverative errors committed during set-shifting as compared 
to vehicle and rolipram alone groups (****P<0.0001). This effect was ameliorated by rolipram co-
infusion with dual combination ($$$$P<0.0001). Perseverative errors committed by co-infusion 
group and the vehicle group were comparable (P>0.05). Further, regressive and never-reinforced 
errors committed by all the groups were comparable (P>0.05). Two-way ANOVA followed by 
Tukey’s post hoc test; n=7 per group. 
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 ERK phosphorylation in mPFC neurons is essential for set-
shifting 
In order to identify the potential signaling cascade downstream of NMDA 
receptors in mediating set-shifting, we attempted to inhibit phosphorylation of ERKs, a 
common downstream signaling event of NMDA-mediated Ca++ influx, and an important 
intermediary transducing NMDA signaling to the nucleus. To this end, groups of naïve 
animals received intra-mPFC infusion of a MEK inhibitor PD98059 prior to testing.  
4.4.4.1 Visual-cue learning and visual-cue retrieval before set-shifting 
In different group of naïve animals, intra-mPFC infusion of MEK inhibitor; 
PD98059 (2.5 g/side) did not affect visual-cue learning on visual-cue day (initial set 
formation) as compared to vehicle group [t(12)=0.3234, P>0.05] (n=7; Figure 4.8 A; 
student’s t-test). Further, visual-cue retrieval on set-shift day was not affected by 
PD98059 treatment [t(6)=0.6882, P>0.05] (n=7; Figure 4.8 B; student’s t-test). 
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Figure 4.8 Effect of PD98059 treatment on visual-cue learning and visual-cue retrieval 
before set-shifting. 
A) On the visual-cue discrimination day, prior intra-mPFC infusion of PD98059 (2.5 g/side) 
did not affect learning of visual-cue discrimination strategy. The number of errors committed 
during the visual-cue learning was comparable between PD98059 and vehicle groups 
(P>0.05). Student’s t-test; n=7 per group. B) On the set-shift day (during the 20 trials prior to 
the response discrimination task), intra-mPFC infusion of PD98059 (2.5 g/side) did not affect 
retrieval of the memory from the previous day (visual-cue discrimination task), as the number 
of errors committed during the 20 visual-cue trials was comparable between the groups 
(P>0.05). Student’s t-test; n=7 per group. 
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4.4.4.2 Trials and errors to criterion during set-shifting 
Results indicate that bilateral infusion of PD98059 into the mPFC impair set-
shifting in naïve rats. PD98059 at dose 2.5 μg per side, significantly impaired animal’s 
ability to shift from one strategy to the other. The number of trials to criterion 
[t(12)=6.963, P<0.0001] as well as number of errors to criterion [t(12)=8.169, P<0.0001] 
were significantly increased following PD98059 infusion compared or vehicle group 
(n=7, each; student’s t-test; figure 4.9 A,B).  
 
  
Figure 4.9 Effect of intra-mPFC infusion of PD98059 on trials and errors to criterion 
during set-shifting. 
A) Intra-mPFC infusion of the PD98059 (2.5 g/side) significantly increased number of 
trials to criterion (****P<0.0001) as compared to vehicle group. Student’s t-test; n=7 per 
group. B) Following infusion of PD98059 (2.5 g/side), rats committed significantly more 
number of errors as compared to the vehicle group (****P<0.0001). Student’s t-test; n=7 
per group. 
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4.4.4.3 Type of errors  
Two-way ANOVA revealed a significant main effect of treatment 
[F(1,6) = 64.95, P=0.0002] as well as type of errors [F(2,12) = 58.57, P<0.0001] 
following 2.5 μg per side of PD98059. Bonferroni’s multiple comparisons test showed 
significant increase in perseverative errors following PD98059 infusion as compared to 
vehicle-treated group (P<0.05) (Figure 4.10). PD98059 treatment did not affect 
regressive or never-reinforced errors compared to vehicle group (P>0.05). 
 
 
 
 
 
 
 
 
  
Figure 4.10 Effect of PD98059 treatment on type of errors during set-shifting. 
Intra-mPFC infusion of PD98059 (2.5 g/side) prior to set-shifting increased number of 
perseverative errors committed significantly as compared to vehicle group (*P<0.05). 
Regressive and never-reinforced errors were remained unaffected by PD98059 (P>0.05). 
Two-way ANOVA followed by Bonferroni’s multiple comparison test; n=7 per group. 
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4.4.4.4 Omissions and latency to response 
Number of omissions committed by PD98059 treated group was comparable to 
vehicle group [t(12)=0.9487, P>0.05] (n=7; Figure 4.11 A; student’s t-test). Latency to 
response for different type of trials was comparable between PD98059 and vehicle 
groups [F(1,6) = 0.000244, P=0.9881] (n=7 Figure 4.11 B; two-way ANOVA). 
  
Figure 4.11 Effect of PD98059 treatment on number of omissions and latency to response 
during set-shifting. 
A) Number of omissions committed by PD98059 treated group were comparable to vehicle 
group (P>0.05). Student’s t-test; n=7 per group. B) Latency to response on extended levers 
during different type of trials was not altered in both PD98059 and vehicle groups (P>0.05). 
Two-way ANOVA; n=7 per group. 
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 Augmenting PKA activity does not affect the set-shifting deficits 
caused by the inhibition of ERK phosphorylation 
Our results so far showed that augmenting PKA activity ameliorates set-shifting 
deficits caused by simultaneous inhibition of D1 and NMDA receptors (i.e., dual 
combination treatment) and inhibiting ERK phosphorylation impairs set-shifting. PKA 
activity may affect NMDA receptor-mediated ERK phosphorylation by targeting multiple 
members along the pathway. The main proposed effect of phosphorylated ERK is on 
transcriptional regulation. Interestingly, PKA translocate to the nucleus and capable of 
affecting transcription including phosphorylating nuclear (cAMP response element-
binding protein) CREB independent of ERK phosphorylation. To verify whether 
augmented PKA activity facilitates set-shifting via ERK phosphorylation or by other 
cascades, we sought to augment PKA activity while inhibiting ERK phosphorylation in 
animals performing set-shifting task. Rats were infused into the mPFC bilaterally with a 
combination of rolipram and PD98059. 
4.4.5.1 Trials and errors to criterion 
Co-infusion of rolipram (2.5 μg/side) and PD98059 (2.5 g/side) did not cause 
any improvement in PD98059-induced set-shifting deficit. Rolipram did not attenuate 
PD98059-induced increased number of trials to criterion [F(2,18) = 24.08, P<0.0001] 
and number of errors to criterion [F(2,18) = 22.38, P<0.0001] (one-way ANOVA 
followed by Bonferroni’s test). Post hoc analysis showed that compared to the vehicle 
group, co-infusion of rolipram and PD98059 resulted in significant increase in number of 
trials to criterion (P<0.001) and number of errors to criterion (P<0.001). Importantly, 
group that received co-infusion did not show any difference in number of trials or errors 
to criterion as compared to the group infused with PD98059 alone (P>0.05) (Figure 4.12 
A, B; one-way ANOVA). 
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Figure 4.12 Effect of rolipram on PD98059-induced set-shifting impairments. 
A) Intra-mPFC infusion of PD98059 (2.5 g/side) significantly increased number of 
trials to criterion during set-shifting as compared to vehicle group (****P<0.0001). Co-
infusing PD98059 with rolipram did not alter number of trials to criterion as compared 
to PD98059 per se group (P>0.05). Further, co-infusion group showed significant 
increase in trials to criterion as compared to vehicle group (***P<0.001). One-way 
ANOVA followed by Bonferroni’s test; n=7 per group. B) Prior treatment with 
PD98059, animals showed a significant increase in number of errors committed during 
set-shifting as compared to vehicle group (****P<0.0001). Combined treatment of 
rolipram with PD98059 did not decrease number of errors to criterion as compared to 
PD98059 alone group (P>0.05). As compared to vehicle, combined infusion group 
showed a significant increase in errors to criterion (***P<0.001). One-way ANOVA 
followed by Bonferroni’s test; n=7 per group. 
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4.4.5.2 Type of errors 
Co-infusion of rolipram (2.5 μg/side) and PD98059 (2.5 g/side) did not attenuate 
PD98059-induced increased perseverative errors. Combined treatment with rolipram and 
PD98059 showed increased number of perseverative errors [F(1,6) = 21.89, P=0.0034] 
(two-way ANOVA; Figure 4.13). Bonferroni’s post hoc analysis showed significant 
increased perseverative errors following the combined treatment as compared to vehicle 
group (P<0.01). Further, the number of perseverative errors seen following co-infusion 
of rolipram and PD98059 did not differ from PD98059 alone treatment group (P>0.05). 
There was no change in regressive and never-reinforced errors across groups (P>0.05). 
 
 
Figure 4.13 Effect of rolipram on PD98059-induced increased perseverance. 
PD98059 infusion in mPFC significantly increased number of perseverative errors as compared to 
vehicle group (***P<0.001). Co-infusion of rolipram with PD98059 did not decrease number of 
perseverative errors committed during set-shifting as compared to PD98059 group (P>0.05). In 
comparison with vehicle group, animals receiving combined infusion showed a significant increase 
in number of perseverative errors committed during set-shifting (**P<0.01). Two-way ANOVA 
followed by Bonferroni’s test; n=7 per group. 
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Figure 4.14 Representative histology and reconstruction of infusion cannulae tracks 
in mPFC. 
A) Photomicrographs showing that the bilateral infusion cannulae targeted the prelimbic 
(PL) region of the mPFC in a representative animal. B) Schematic images of successive 
coronal sections (adapted from Paxinos and Watson, 2007) showing the location of the 
ends of the infusion cannulae in all animals used in the present study (n=48).  
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4.5 Discussion 
We found that, set-shifting impairments caused by intra-mPFC infusion of dual 
combination were reversed co-infusion of PDE4 inhibitor- rolipram. Further, inhibiting 
ERKs phosphorylation by MAPK inhibitor (PD98059) impaired set-shifting, while co-
infusion of rolipram failed to ameliorate this impairment. Surprisingly, disrupting D1-
NMDA receptor cross-talk by inhibition of Fyn kinase in the mPFC did not affect set-
shifting performance.  
 Effect of PKA elevation on dual combination-induced set-shifting 
deficits 
We have shown that co-infusing D1 and NMDA receptor antagonists into the 
mPFC impaired set-shifting at doses that when infused separately failed to affect set-
shifting performance (see 3.4.2). We found that increasing PKA levels in mPFC by intra-
mPFC infusion of PDE4 inhibitor, rolipram, attenuated this dual combination treatment-
induced set-sifting impairments by decreasing the number of trials and errors to criterion 
as well as the number of perseverative errors committed during set-shifting. Several 
behavioural and electrophysiological studies have shown that PKA signaling cascade 
may underlie the D1-NMDA receptor interaction in the PFC (Snyder et al., 1998; Aujla 
and Beninger, 2001; Wang and O’Donnell, 2001; Baldwin et al., 2002a; Flores-
Hernández et al., 2002; Tseng and O’Donnell, 2004; Kruse et al., 2009; Li et al., 2010; 
Cahill et al., 2014). Increasing levels of PKA should, therefore, override the deleterious 
effects of combined D1 and NMDA receptor antagonism, and our results support this 
notion.  
Rolipram was chosen based on its proven effectiveness for the PFC where the 
most predominant PDE is of type 4 (Bolger et al., 1994; Suvarna and O’Donnell, 2002; 
Richter et al., 2013). Our results are in accordance with Rodefer et al. (2012) who 
showed that rolipram reversed set-shifting impairment caused by sub-chronic 
phencyclidine (PCP, NMDA receptor antagonist) treatment in rats. In addition, number of 
behavioural studies have reported effectiveness of rolipram in ameliorating cognitive 
deficits due to NMDA antagonism (Zhang et al., 2000, 2004, 2005; Davis and Gould, 
2005; Rodefer et al., 2005). 
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 We found that intra-mPFC infusion of rolipram alone in naïve rats did not 
improve their set-shifting performance. In accordance with our results, Rodefer et al. 
(2005) failed to see improvement in the performance in set-shifting using PDE10 
inhibitors per se. However, Nikiforuk et al. (2016) reported improvement in set-shifting 
performance in rats following infusion of a PDE10 inhibitor into the striatum. Our study 
investigated the role of PFC and used an operant conditioning-based set-shifting task 
where as Nikiforuk et al. (2016) studies striatal role and used a digging task-based set-
shifting, and strategies used by animals may differ between these different type of tasks. 
 From available preclinical data as well as our findings, it seems that PKA 
activators (phosphodiesterase inhibitors) improve cognition in animals. Executive 
functions including working memory, attention and set-shifting were found to be 
improved (Nikiforuk et al. 2016; Zhang et al., 2000, 2004, 2005; Davis and Gould, 2005; 
Rodefer et al., 2005). Potential use of rolipram like compounds as cognitive enhancers is 
being tested in clinical trials by different pharmaceutical companies against cognitive 
symptoms associated with CNS disorders including schizophrenia and Alzheimer’s 
disease (Houslay et al., 2005; Kanes et al., 2007; García-Osta et al., 2012; Maurice et al., 
2014). Effect of inhibiting ERK cascade on set-shifting. 
Our results for the first time indicate that inhibiting ERK phosphorylation in the 
mPFC impaired set-shifting without affecting new learning or retrieval of memory. Intra-
mPFC infusion of a MAPK inhibitor, (PD98059; 2.5 g/side), increased number of trials 
and errors to criterion while performing set-shifting task and significantly increased 
perseverative errors.  
 Stimulation of NMDA receptor induces activation of MAPK signaling cascade 
leading to phosphorylation of ERKs and this plays an important role in learning 
(Chandler et al., 2001; Krapivinsky et al., 2003; Shiflett et al., 2010; Shiflett and 
Balleine, 2011). Although involvement of NMDA receptors in set-shifting is well 
documented (Stefani et al., 2003; Stefani and Moghaddam, 2005), signaling mechanisms 
downstream to receptors regulating set-shifting are not clear. Sarantis et al. (2009) has 
reported that synergism between D1 and NMDA receptors in the PFC and hippocampus 
is ERK-dependent. Recognizing a potential role of D1 and NMDA receptor synergism in 
regulating set-shifting, we propose that the ERK signaling was disrupted following co-
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infusion of D1 and NMDA receptor antagonists in the mPFC causing set-shifting deficits 
in rats (Figure 4.15). Effect of PKA activation on set-shifting deficit caused by inhibition 
of ERK signaling 
Our results showed that augmenting PKA levels in the mPFC ameliorates set-
shifting deficits caused by the combined blockade of D1 and NMDA receptors, 
suggesting an important role for PKA in D1-NMDA receptor synergism in mediating set-
shifting. We also found that ERK phosphorylation, a downstream effect of NMDA 
stimulation in the PFC, is critical for set-shifting. The most widely studied effect of ERK 
phosphorylation is to affect transcriptional regulation. Interestingly, several transcription 
factors, such as CREB, can be activated by phosphorylated ERKs as well as by activated 
PKA trafficking into the nucleus. Consequently, we tested whether augmenting PKA 
would compensate for impaired ERK phosphorylation in relevance to set-shifting. To this 
end, we investigated effect of mPFC infusion of rolipram (2.5 g/side), the regimen 
ameliorated the deficits following dual combination treatment, in presence of PD98059 
(2.5 g/side) on set-shifting. Surprisingly, we did not see any effect of rolipram on 
PD98059-induced set-shifting impairment. Therefore, it is likely that increased PKA 
cannot compensate for the impaired ERK function, and ERK is acting downstream of 
PKA. 
Zhang et al. (2004) reported that PKA elevation mediated by PDE4 inhibitors 
reverse the reference memory impairment caused by MAPK inhibitors in rats. In that 
study, intra-hippocampus infusion of MAPK inhibitor U0126 impaired working and 
reference memory in a radial arm maze task. Co-infusion of rolipram into the 
hippocampus reversed the reference memory deficits with no effect on working memory. 
Mechanism subserving reference memory might be different from that underlying set-
sifting. In fact, our results show that doses of blockers and receptor antagonists that 
impair set-shifting do not affect memory formation or retrieval. Further, in the same 
study, it was shown that, rolipram dose which reversed U0126-induced reference 
memory deficit, did not ameliorate U0126-induced decreased ERK-phosphorylation. This 
suggests that rolipram-mediated increased PKA activity might have reversed the 
reference memory impairment via a different signaling cascade (Yan et al., 2016). 
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Interestingly, activation of D1 receptor in mPFC, presumably activating PKA signaling, 
also increased phosphorylation of NMDA receptor subunits, and this effect was blocked 
by inhibitors of ERK phosphorylation (Nagai et al., 2007; Sarantis et al., 2009) 
suggesting a cascade involving D1  PKA  ERK  NMDA, and our findings are in 
support of this possibility (Figure 4.15). Thus, based on mentioned studies, we speculate 
that phosphorylated ERKs may be regulating set-shifting behaviour by targeting 
cytoplasmic substrates. It may be possible that phosphorylated ERKs are responsible to 
phosphorylate NMDA receptors and increasing their functioning which ultimately 
benefits set-shifting behaviour as proposed by Sarantis et al. (2009). Further, increased 
activation of NMDA receptors found to increase activation of PKA (Roberson and Sweatt 
1996; Jay et al. 1998; Nayak et al. 1998). As our results suggest that PKA restores 
abnormal set-shifting behaviour, overall effect of increased ERKs phosphorylation should 
promote set-shifting behaviour. 
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Figure 4.15 Possible mechanisms underlying D1-NMDA receptor interaction 
mediated set-shifting. 
We observed that, co-infusing D1 and NMDA receptor antagonists in the mPFC at sub-
effective doses (dual combination) impaired set-shifting in rats. This impairment was 
reversed by rolipram infusion in the mPFC. Further, inhibiting ERKs phosphorylation in 
mPFC also caused set-shifting deficits and co-infusion of rolipram failed to reverse these 
impairments. Based on available literature, it is possible that, D1 and NMDA receptor 
antagonists at sub-effective doses act synergistically at the level of molecular signalling 
affecting behaviour (Baldwin et al., 2002b). It is known that, D1 and NMDA receptors 
stimulation triggers PKA and ERK pathways respectively (Chandler et al., 2001; Wang 
et al., 2002). Further, PKA-ERK signalling cascades interact with each other where, D1 
receptor stimulation or combining sub-effective doses of D1 and NMDA receptor 
agonists resulted in increased phosphorylation of ERKs as well as NMDA and AMPA 
receptor subunits; and this effect was blocked by MAPK inhibitor (Sarantis et al., 2012). 
Based on our findings and the literature, we propose that, set-shifting is regulated by 
PKA as well as ERK signalling and ERK is downstream to PKA as rolipram did not 
reverse the set-shifting deficits caused by inhibition of ERK phosphorylation. Thus, it 
seems that, set-shifting is regulated by D1  PKA  ERK  NMDA pathway.  
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 Effect of inhibiting Src kinase on set-shifting  
Besides PKA and ERK signaling, evidence indicates that D1-NMDA receptor 
interaction may involve direct physical coupling and functional cross-talk (Lee et al., 
2002; Fiorentini et al., 2003; Cepeda and Levine, 2006; Scott et al., 2006). This protein-
protein interaction is associated with phosphorylation and trafficking of NMDA receptor 
subunits from cytoplasm to the cell membrane (Hallett et al., 2006; Gao and Wolf, 2008; 
Hu et al., 2010). Fyn kinase (a member of Src family kinase) mediates D1-induced 
increased surface expression of NMDA receptors in the PFC (Dunah et al., 2004; Hu et 
al., 2010). Consequently, we predicted that Fyn kinase activity might mediate part of the 
D1-NMDA interaction associated with set-shifting. Intra-mPFC infusion of PP2 (3 
ng/side) did not affect set-shifting in rats. The dose of PP2 was chosen from previous 
studies where PP2 impaired cognitive functions (Bevilaqua et al., 2003) and suppression 
of NR2B phosphorylation (Grosshans and Browning, 2001; Lu et al., 2015). Unlike our 
finding, Bevilaqua et al. (2003) reported that, infusing the same dose of PP2 into the 
hippocampus impaired memory formation and retrieval. In addition, although mice with 
Fyn mutation showed impaired LTP and spatial learning in water maze task (Grant et al., 
1992), they did not show spatial learning deficit in radial arm maze (Miyakawa et al., 
1996); neither they had deficits in conditioned taste aversion (Schafe et al., 1996). A 
recent post-mortem study demonstrated evidence for reduced Src-family kinase activity 
in the PFC of patients with schizophrenia (Hahn, 2011; Banerjee et al., 2015). Among 
other cognitive symptoms, impaired behavioural flexibility and poor performance in 
WCST are consistent findings in these patients (Rosse et al., 1991; Abbruzzese et al., 
1996; Haut et al., 1996; Waford and Lewine, 2010). Based on these evidence it was 
proposed that impaired Src kinase function in the PFC might serve as a hub for the 
cognitive dysfunction of schizophrenia (Banerjee et al., 2015). Although relatively less is 
known of signaling mechanisms of Src kinase in the PFC, our results indicate that Src 
kinase activity is unlikely playing a major role in set-shifting ability.  
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 General discussion 
Our studies investigated executive function (set-shifting), interaction between 
dopamine and glutamate neurotransmitters regulating set-shifting and the signaling 
mechanisms underlying the interaction. We found that, dopamine D1 and glutamate 
NMDA receptors synergistically regulate set-shifting behaviour. We also found that D1-
NMDA interaction in the mPFC regulates set-shifting behaviour through PKA pathway. 
Further, we found obligatory role of ERK signaling cascade in the mPFC mediating set-
shifting behaviour. For the first time, our studies explored role of molecular mechanisms 
associated with set-shifting behaviour in rats. Our results propose possibility of targeting 
molecular signaling pathways including PKA and ERKs for new drug discovery and 
development. 
 In our first study, we examined the role dopamine and glutamate in regulating set-
shifting particularly when their activities are decreased only slightly. We hypothesized 
that a minimal loss of glutamate and dopamine activity in certain brain areas as long as 
they occur simultaneously would impair set-shifting and promote perseverative errors. 
We employed an operant conditioning-based set-shifting task (Floresco et al., 2008) in 
rats to determine behaviourally sub-effective doses of D1 or NMDA receptor antagonists 
using dose-response studies. We then injected the behaviourally sub-effective doses of 
D1 and NMDA antagonists together in naïve adult rats systemically to test the 
hypothesis. Results showed that the combined systemic administration of behaviourally 
sub-effective doses of NMDA and D1 receptor antagonists resulted in significant 
impairment in set-shifting and increased perseverative errors. To our knowledge, this is 
the first experimental evidence of an interaction between glutamate and dopamine 
systems in regulating set-shifting behaviour in rats. 
Based on post-mortem studies of schizophrenia brains consistently showing 
evidence of considerable loss of GABA, dopamine or glutamate activity in the PFC, it 
was widely believed that suppression of any one of these neurotransmitters may facilitate 
impairment in executive function seen in schizophrenia (Okubo et al., 1997; Akil et al., 
1999; Goldman-Rakic et al., 2004; Gonzalez-Burgos et al., 2011; Hu et al., 2015). 
However, recent studies using in vivo MRS and PET have identified that levels of 
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glutamate, dopamine and GABA in the dlPFC and thalamus are normal or slightly altered 
in schizophrenia patients in comparison to control groups (Théberge et al., 2007; 
Ohrmann et al., 2007; Galińska et al., 2009; Rowland et al., 2009; Aoyama et al., 2011; 
Seese et al., 2011; Szulc et al., 2011; Goto et al., 2012; Kegeles et al., 2012; Frankle et 
al., 2015; Slifstein et al., 2015). Above MRS and PET findings suggest that the extent of 
decrease of neurotransmitter function foreseen based on findings from post-mortem 
studies, may not be applicable in living patients of schizophrenia, and if at all, the 
differences may be subtle, perhaps due to compensatory mechanisms. Furthermore, 
recent theories postulate that certain GABA abnormalities in schizophrenia might be 
compensatory (Gonzalez-Burgos et al., 2011; Lewis, 2014). In addition D1 and NMDA 
receptors are found to regulate cognitive functions in animal models (Baldwin et al., 
2002; Yang and Chen, 2005; Kruse et al., 2009; Wang et al., 2012a). Consequently, we 
hypothesized that subtle abnormalities in the glutamate and dopamine neurotransmitter 
systems in functionally-connected cortical and subcortical areas may cooperate 
synergistically to impair executive function in schizophrenia, an experimental 
consideration never addressed in previous preclinical rodent models as they only targeted 
single neurotransmitter system at a time.  
In our first study, we chose systemic route of drug administration to achieve 
blockade of receptor function in multiple brain areas to be in agreement with the proposal 
that executive function is regulated by neuronal circuits rather than single brain nucleus 
(Floresco et al., 2009). As predicted results showed a significant increase in perseverative 
errors following combined systemic administration of behaviourally sub-effective doses 
of D1 and NMDA receptor antagonists. Interestingly, animal studies have shown that 
inactivation of mPFC or MDT results in increased perseverative errors (Block et al., 
2007; Floresco et al., 2009). Our finding is also in line with the clinical literature where 
schizophrenic patients performing WCST show increased perseverance (Crider, 1997; 
Gooding et al., 1999; Prentice et al., 2008; Orellana and Slachevsky, 2013), points to 
abnormal glutamate and dopamine function in multiple brain areas.  
Based on preclinical studies Floresco (2013) proposed that inactivation of mPFC 
or MDT or disconnecting these two nuclei results in increased perseverative errors while 
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no change in regressive or never-reinforced errors. In our first study, systemic co-
administration of NMDA and D1 antagonists produced a pattern of error profile with 
increased perseverative errors that is similar to that proposed following damage to mPFC 
and MDT or their connection (Block et al., 2007; Floresco et al., 2009). The results 
pointed to mPFC and MDT as the most likely sites responsible for sub-effective doses of 
D1 and NMDA receptor antagonists to act to produce deficits in set-shifting and 
increased perseverative errors. Considering parallels with schizophrenia, we propose that 
systemic administration of D1 and NMDA antagonists in naïve adult rats may model 
certain aspects of cognitive deficits of schizophrenia and may form a potential high 
throughput screening tool for testing drug candidates against cognitive symptoms of 
schizophrenia. 
As reasoned above, systemically-administered D1 and NMDA antagonist 
combination has likely acted in the mPFC and MDT to impair set-shifting and to increase 
perseverative errors. Since MDT receive very sparse dopamine innervation (Block et al., 
2007; Floresco et al., 2008, 2009) and dopamine abnormalities have never described in 
the MDT of patients with schizophrenia, a disease characterized by executive functional 
deficits and increased perseverative errors, we considered the mPFC as the most likely 
candidate site. Consequently, in the second study, effects of combined blockade of D1 
and NMDA receptors were investigated in the mPFC. However, it is still possible that D1 
blockers might be acting in the PFC while NMDA blockers simultaneously acting in 
MDT (or even the hippocampus) to cause their combined effects, as these are structurally 
and functionally interconnected centers (Vertes, 2006; Floresco et al., 2009). In the 
second study, following direct microinfusion of various doses of D1 and NMDA 
antagonists separately into the mPFC bilaterally, we determined the behaviourally sub-
effective doses for each of these blockers. When these seemingly ineffective doses were 
combined, increased number of trials and errors to criterion were evident while 
performing set-shifting task, suggesting that the mPFC is one of the sites where 
synergism between D1 and NMDA receptor antagonism might be occurring. The 
impaired set-shifting was accompanied by significant increase in perseverative errors 
following intra-mPFC co-infusions. This finding is in accordance with clinical studies in 
schizophrenic patients performing WCST (Gooding et al., 1999; Prentice et al., 2008; 
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Desai et al., 2017). It appears that PFC may play an important role in executive function 
and its abnormality may manifest perseverative errors across species.  
From our results, it seems that normal functioning of dopamine and glutamate 
neurotransmitters is essential for executive functioning and abnormalities among them 
lead to deficits. This notion opens doors for different strategies that could be used to 
ameliorate executive dysfunction due to abnormal functioning of PFC. For example, 
using drugs such as PDE4 inhibitors (rolipram) to increase the levels of cAMP, a 
downstream effector of D1 stimulation, and obligatory activator of PKA cascade. Based 
on our finding that co-infusion of D1 and NMDA blockade would cause impairment of 
set-shifting while only one of these drugs at the same dose is unable cause this effect 
suggesting that for normal set-shifting, co-incident activation of both D1-NMDA 
receptors is necessary. Thus, we postulated use of multi-drug therapy strategy (i.e., 
combining antipsychotic drugs and cognitive enhancers) could be more beneficial rather 
than conventional mono-therapy approach used so far in schizophrenia. Nevertheless, 
more comprehensive understanding of the signaling cascade mediating set-shifting and 
preventing perseverative errors is essential for future strategies to investigate potential 
novel pharmacological targets. It is important to note that virtually nothing is known of 
signaling beyond neurotransmitter receptors when it comes to set-shifting or 
perseverance. Consequently, in the third study, we sought to investigate signaling 
mechanisms underlying synergism between D1 and NMDA receptor antagonism in the 
mPFC and those cascades important for set-shifting and preventing perseverative errors. 
In the third study, we found that synergistic interaction between dopamine D1 and 
glutamate NMDA receptor antagonists cause impairment of set-shifting and this effect 
was reversed by intra-mPFC co-infusion of PDE4 inhibitor (rolipram). This is an 
example of using adult naïve rats with combined infusion of D1 and NMDA antagonists 
into the mPFC as a putative model of executive function deficits of schizophrenia to 
investigate a potential effect of cognitive enhance, a proposal we made above. Findings 
from this study suggested that D1-NMDA receptor interaction might use PKA signaling 
pathway and elevating PKA levels using rolipram rescues set-shifting from effect of dual 
combination of antagonists. Our findings are in accordance with previously published 
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studies where PDE inhibitors successfully rescued animals from certain types of 
cognitive deficits (Rodefer et al., 2005, 2012; Nikiforuk et al., 2016). In addition to this, 
use of PDE inhibitors in number of CNS disorders has been initiated (Fore review, 
Maurice et al., 2014). Post-mortem studies as well as imaging studies in schizophrenic 
patients have showed abnormal dopamine neurotransmission in the PFC (Okubo et al., 
1997; Akil et al., 1999; Harrison, 2000; Abi-Dargham, 2003; Howes et al., 2015). This 
lead to notion that, increasing D1 receptor activity in PFC would be beneficial for 
cognition. In line with the hypothesis, Rosell et al. (2015) found that, D1 receptor agonist 
treatment was helpful to improve cognition in patients with schizotypal personality 
disorder (SPD). Although peripheral side-effects of the drugs tested prevented further 
human studies (Salmi et al., 2004).  
Another novel finding of our study is that, ERK signaling pathway is essential for 
normal set-shifting and inhibition of ERK1/2 phosphorylation using a MAPK inhibitor 
PD98059 resulted in increased perseverative errors. Interestingly, PD98059-induced set-
shifting impairments were not rescued by co-infusion of rolipram suggesting that ERK 
pathway is downstream to PKA regulating set-shifting. Association of ERK signaling in 
cognition has been studied extensively (Kelly et al., 2003; Duvarci et al., 2005; 
Giovannini, 2006; Peng et al., 2010). In addition, evidence suggesting attenuated ERK 
signaling in the PFC of schizophrenic patients has been reported in post-mortem studies 
(Yuan et al., 2010; Hirayama-Kurogi et al., 2017). From our results and the literature 
published on ERK signaling and its role in cognition, it seems that ERK could be a 
potential target for development of drugs against cognitive deficits. In this regard, use of 
ERK pathway modulators as therapeutic agents has been proposed in literature (Pearson 
et al., 2001; Peng et al., 2010; Eishingdrelo, 2013). Researchers have investigated 
possible use of modulators of ERK signaling in animal models of cognition, fragile X 
syndrome, autism and reward (David Sweatt, 2001; Gerdjikov et al., 2004; Beninger and 
Gerdjikov, 2005; Weng et al., 2008; Peng et al., 2010; Shiflett and Balleine, 2011; Wang 
et al., 2012b, 2015; Papale et al., 2016; Sun et al., 2016). Further understanding of 
signaling mechanisms is necessary for this line of effort to improve cognition. 
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A Number of studies have explored ERK signaling and its association with 
chronic or sub-chronic conditions including addiction, stress or memory consolidation. It 
is generally considered that phosphorylated ERK1/2 would translocate to the nucleus and 
interact with cAMP Response Element-Binding Protein (CREB) and other nuclear targets 
(Roberson et al., 1999; Dudman et al., 2003; Waltereit and Weller, 2003). In our studies, 
rats were subjected to set-shifting following acute intra-mPFC treatment with MAPK 
inhibitor (PD98059). This suggests that, even acute blocking of ERK signaling impairs 
set-shifting. Preliminary results from our laboratory suggest that in the context of set-
shifting, phosphorylated ERK1/2 might be acting mainly in the cytoplasm in mPFC 
neurons, a proposal suggested previously by Sarantis et al. (2009). Although ERK 
interactions with its nuclear targets like CREB cannot be ruled out.  
In our study, inhibition of ERK phosphorylation with MAPK inhibitor (PD98059) 
impaired set-shifting; and rolipram failed to attenuate this impairment. In addition to this, 
disrupting cross-talk between D1 and NMDA receptors by inhibiting Fyn kinase did not 
affect set-shifting. To our knowledge, this is the first study investigating signaling 
mechanisms underpinning D1-NMDA receptor synergistic interaction regulating set-
shifting behaviour in rats. 
5.1 Future directions 
Taken together, present series of studies represent a big step forward towards 
understanding executive function and underlying molecular mechanisms associated with 
executive function deficits. We revealed molecular signaling pathways regulating set-
shifting behaviour and facilitating perseverative errors. This information will likely pave 
future research endeavours in direction of developing potential drug candidates to 
improve executive functions by targeting unconventional molecular pathways. With the 
novel information, there are a number of new questions rise. From our studies, it seems 
that multiple neurotransmitters act simultaneously to mediate successful executive 
function. Future studies in animals as well as in human may use this approach to find out 
potential therapeutic combinations of drugs to improve cognitive symptoms. 
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In the final study, our results suggest critical and obligatory involvement of ERK 
signaling mediating set-shifting. Further investigations are needed to find out what targets 
in cytoplasm/nucleus ERK interact with to mediate set-shifting. Future research should 
also address if NMDA/D1 independent activation of ERK pathway in mPFC would 
ameliorate set-shifting deficits in putative models of schizophrenia.  
Importance of dopamine-glutamate interactions in implications for development 
of neuropsychiatric treatments has attracted researchers (Castner and Williams, 2007; 
Wang et al., 2012a). For example, conventional medications used to suppress positive 
symptoms of schizophrenia mainly act by blocking dopamine D2 receptors. On the other 
hand, cognitive and negative symptoms are associated with D1 receptors in the PFC 
(Seamans et al., 1998; Akil et al., 1999; Goldman-Rakic et al., 2004). Similarly, 
glutamate NMDA receptors have become an important target as preclinical studies have 
proven that, blocking NMDA receptor function induces positive, negative and cognitive 
symptoms of schizophrenia whereas enhancing NMDA receptor functions potentially 
reverse these impairments (Fletcher et al., 2005; Nabeshima et al., 2006; Mouri et al., 
2007; Hashimoto et al., 2008; Seillier and Giuffrida, 2009; Castañé et al., 2015). 
Although the success of drug candidates modulating D1 or NMDA receptors seems very 
promising in preclinical studies, recent clinical trials using these modulators have met 
with limited success (Chaves et al., 2009; Tandon et al., 2010; Miyamoto et al., 2012; 
Menniti et al., 2013; Dimitrelis and Shankar, 2016). The main reason behind failure of 
compounds to pass clinical trials is that simply blocking or enhancing receptor functions 
would result in unintended side-effects. Further, number of conventional preclinical 
models cause impairments in animal behaviours following use of high dose of antagonists 
which not the case in actual physiology. In this context, our results have indicated that 
future studies should model cognitive deficits using minimal but combined suppression 
of receptor/molecular function to mimic those changes might be happening in living 
patients with tremendous compensatory mechanisms trying to normalize the defect. 
Finally, targeting receptor interactions and molecular pathways might be a useful avenue 
in correcting pathological imbalance in signaling mechanisms of neurotransmitters rather 
than using molecules that bind to cell surface receptors. 
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5.2 Limitations: 
In pilot testing for our first study, we tested individual dose-dependent effects of 
glutamate NMDA receptor antagonist (MK-801), dopamine D1 receptor antagonist SCH 
23390 and GABA A receptor antagonist bicuculline on set-shifting behaviour following 
subcutaneous injections. We obtained behaviourally sub-effective doses of each 
antagonists. To study any interactions, we injected all three sub-effective doses of 
antagonists simultaneously and rats were subjected to set-shifting task. Animals treated 
with combined three antagonists showed noticeable abnormalities in behaviour including 
reduced latency to response on the levers as well as they did not eat food pellets 
following correct responses for 20-25 trials. On the other hand, rats treated with 
combined behaviourally sub-effective doses of D1 and NMDA receptors showed only 
behavioural flexibility deficits not affecting latency or omissions committed during set-
shifting. For the same reason, we used D1 and NMDA receptor antagonists in our first 
study. 
Further, in our first study, while testing dose-dependent effects of dopamine D1 
receptor antagonist SCH 23390 on set-shifting behaviour, we observed that subcutaneous 
injections of higher dose of SCH 23390 (0.01 or 0.02 mg/kg) caused noticeable motor 
deficits and increased response latency, which resulted in a significant number of 
omissions in both the visual-cue retrieval and set-shifting trials, and ultimately a failure to 
complete the sessions (data not shown). For the same reason, we could not find effective 
dose of SCH 23390 in our study and used lower dose of the antagonist which did not 
affect locomotor activity and set-shifting in rats.In our last study (Chapter-IV), we 
examined role of prefrontal cortical Fyn kinase in set-shifting behaviour in normal rats. 
We found that used dose of Fyn kinase inhibitor-PP2 in the mPFC did not affect set-
shifting behaviour. Although, the dose of PP2 was chosen from previous studies where 
PP2 impaired cognitive functions (Bevilaqua et al., 2003) and suppression of NR2B 
phosphorylation (Grosshans and Browning, 2001; Lu et al., 2015), running western blot 
studies to see if there is actual decreased NMDA receptor subunit phosphorylation would 
confirm the previous findins. 
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